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ABSTRACT
Insights into the cyclooxygenase pathway in a progressive rat model of Parkinson’s disease
induced by prostaglandin J2: protection with ibuprofen
by
Chuhyon Corwin

Advisor: Dr. Maria E. Figueiredo-Pereira

Parkinson’s disease (PD) is a neurodegenerative disease with aging as a major risk factor.
Its defining symptoms are motor deficits that are primarily associated with dopaminergic
neuronal loss in the substantia nigra pars compacta (SNpc) in the midbrain. Post-mortem PD
brains exhibit abnormal intraneuronal inclusions of α-synuclein and ubiquitinated protein
aggregates known as Lewy bodies, a hallmark of PD pathology.
Currently, there is no validated biomarker for PD. Especially the early stage of PD is
difficult to detect as the pathology develops progressively. While symptom-managing treatments
are available, there is no neuroprotective treatment as of yet, mainly due to the unknown cause of
PD. Animal models of PD have greatly expanded our knowledge on different aspects of PD.
However, each has challenges on closely mimicking PD’s major pathological conditions,
especially the progressive nature of the pathology. Among the existing PD animal models, a
shared feature is neuroinflammation, which has been increasingly implicated in the development
of PD by findings from genome-wide association studies, PD-risk genes, environmental risk
factors and post-mortem studies. Transition of acute neuroinflammation to the chronic state is
critical in the development and worsening of neurodegeneration associated with inflammation.
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The cyclooxygenase (COX) pathway is a major contributing factor to the development of
PD. Firstly, COX-2 is upregulated in the substantia nigra of PD patients. Secondly, existing
genetic and toxin models of PD indicate the involvement of the COX pathway. Thirdly,
epidemiological studies report the effect of non-steroid-anti-inflammatory drugs (NSAIDs) in
lowering PD risk. However, NSAIDs are not an ideal treatment against PD due to their serious
side effects. Prostaglandins are products of the COX pathway but their profile and role in the
progression of PD pathology are not fully understood. As endogenous products of
neuroinflammation, prostaglandins may be highly relevant to the etiology of PD.
The overall goal of my studies was to gain insights into how prostaglandins contribute to
PD neurodegeneration in vivo.
Goal 1: Establish a rat model of neuroinflammation displaying parkinsonian-like
pathology induced by the highly neurotoxic prostaglandin J2 (PGJ2), and characterize the
impact of PGJ2 on key factors of the PGD2/J2 signaling pathway (Chapter 2).
We found that unilateral nigral PGJ2-microinfusions induced progressive PD-like
pathology in the rats. PGJ2-treated rats exhibited dose-dependent and progressive dopaminergic
neuronal loss in the SNpc, correlated motor deficits, and gliosis involving microglia and
astrocytes. Ibuprofen, an NSAID, prevented most of the PD-like pathology shown in PGJ2treated rats.
We explored the effect of PGJ2-treatment on COX-2, lipocalin-type PGD2 synthase (LPGDS), PGD2/J2 receptor 2 (DP2), and 15-hydroxyprostaglandin dehydrogenase (15-PGDH), a
PG-deactivating enzyme. We found that COX-2, L-PGDS, and 15-PGDH levels increased
significantly in PGJ2-treated rats compared to controls in the SNpc DA neurons. DP2 receptors
were found predominantly expressed on dopaminergic neurons. The levels of COX-2 and L-
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PGDS co-localization in microglia were increased upon PGJ2-treatment. However, 15-PGDH
levels were did not differ among all rat groups, while high levels of 15-PGDH were detected in
SNpc oligodendrocytes.
Goal 2: Assess chronic neuroinflammation in the PGJ2-induced rat model in vivo
with micro-PET imaging (Chapter 3).
We performed µPET imaging with the translocator protein (TSPO) radioligand
[11C]PK11195 at two different time points (weeks four and eight), post DMSO and PGJ2injections. Higher [11C]PK11195 uptake was observed in rats that received two PGJ2-injections
compared to controls (DMSO-treated) at both time points, indicating chronic glial activation.
Conclusion: our studies establish that the PGJ2-induced rat model recapitulates the
progressive nature of PD pathology albeit in a relatively short term. Chronic neuroinflammation
exhibited in the PGJ2 rat model of PD was assessed with PET imaging in vivo. Studies with the
PGJ2-induced rat model of PD have potential to identify and optimize treatments against
neurotoxic inflammation, and to evaluate novel PET radiotracers for neuroinflammation. Our
studies with the PGJ2-induced rat model of PD, strongly support that therapeutic targets
downstream of cyclooxygenases, such as DP2 receptors and L-PGDS, have potential against PD
pathology.
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CHAPTER I

INTRODUCTION

1.a. Parkinson’s disease and neuroinflammation
1.b. Prostaglandin J2 as an endogenous product of the cyclooxygenase pathway
1.c. Advantages of developing a rat model of neuroinflammation that develops
parkinsonian-like pathology

Chuhyon Corwin

Department of Biology,
Hunter College of the City University of New York,
New York, New York 10065
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1.a. PARKINSON’S DISEASE AND NEUROINFLAMMATION
1.a.1. An overview of Parkinson’s disease
Parkinson’s disease (PD) is the second-most common form of neurodegenerative disorder,
affecting one in 100 people over age 60. PD is a chronic disease that slowly progresses over the
years and its progression rate highly varies among individuals until symptoms reach irreversible
milestones such as postural instability, dementia and death 4 and its diagnosis is confirmed postmortem.
PD pathology is characterized by the progressive loss of dopaminergic (DA) neurons in
the substantia nigra pars compacta (SNpc) and the presence of neuronal protein aggregates
known as Lewy bodies that include α-synuclein and ubiquitinated proteins. DA neuronal loss in
the SN is mainly responsible for the defining motor symptoms of PD, such as bradykinesia and
muscular rigidity, but it is not the only factor attributed to PD pathology. As the disease
progresses, non-DA neurons also degenerate and the affected brain region exceeds the area of the
SN. Neuronal protein aggregates are found in various regions of the brain. Thus, patients with
PD also experience non-motor symptoms involving sleep and the olfactory, autonomic, sensory
and pain systems (reviewed in 5 and 6). However, how the disease spreads to other brain regions
is not clearly determined and is being investigated in two main directions: by propagation
through synaptic connectivity throughout the brain network, or by cell or region-specific
vulnerability 7;8.
There are two major approaches in the treatment of PD: symptomatic and neuroprotective.
For the symptomatic therapy, L-3,4-dihydroxyphenylalanine (L-dopa), the precursor of
dopamine, remains as the gold standard since the 1960s. As the PD motor symptoms appear
when the dopamine level in the brain is reduced by 70-80% 9, L-dopa alleviates motor symptoms.
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However, L-dopa is not disease-modifying, therefore DA neuronal degeneration continues as PD
pathology progresses. In addition to medication alone, deep brain stimulation (DBS) can be used
for further improvement in motor symptoms. Though DBS has been used for PD for three
decades, its exact mechanism is unknown and it is accompanied by complications involving the
surgeries

10

. Among surgical strategies, stem cell and reprogrammed cell transplantations are

considered as neuroprotective treatments to restore DA neuronal degeneration. However, there
are still major challenges to overcome including the safety concern and potency of the treatment
11

. With multiple failures of pharmacological treatments in the later-stage of clinical trials, most

recently by Phytopharm in 2013

12

and Acorda Therapeutics in 2017

13

, neuroprotective

treatments to slow or reverse PD progression remain nonexistent.
In the meantime, various non-pharmacological treatments, such as exercise, are being
explored to improve the quality of life of PD patients 14. Moreover, the growing number of failed
attempts to develop neuroprotective treatment is being attributed to the need for (a) improved
preclinical animal models to advance the understanding of the heterogeneous PD pathology
throughout the disease progression, and (b) effective evaluation means of diagnostics as well as
therapeutics.
1.a.2. Neuroinflammation and PD
Neuroinflammation is a localized defense response of the nervous tissue to a variety of
cues

including

traumatic

brain

injury,

stroke,

infection,

and

toxic

metabolites.

Neuroinflammation is also a non-specific response as it always results in microglia and astrocyte
activation independently of the initiating cue. Acute inflammation is resolved immediately after
the injured site is healed. However, neuroinflammation is widely regarded as chronic
inflammation of the central nervous system (CNS) that extends beyond the original injury and
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spreads to healthy areas.
While there is no wide consensus yet on the exact cause of PD, genetic and
epidemiological studies confirm that neuroinflammation plays a critical role in the
neuropathology and progression of PD. Firstly, genetic factors are thought to be related to
neuroinflammation. Genome-wide association studies (GWAS) reported that variations in loci
encoding immune-associated genes such as human leukocyte antigen (hla), bone marrow stromal
cell antigen 1 (bst1), and triggering receptor expressed on myeloid cells 2 (trem2) are genetic
risk factors for PD

15;16

. In addition, PD-associated mutations in the genes α-synuclein, lrrk2

(leucine-rich repeat kinase 2), parkin and pink1 (PTEN-induced putative kinase 1) were shown
to be linked to the inflammation regulatory pathway 15. α-Synuclein has become a topic of active
research since its mutation was the first identified genetic factor linked to PD

17

. For example,

postmortem PD brains exhibit abnormally high level of α-synuclein, particularly the insoluble
form

18

. Moreover, α-synuclein overexpression and neuroinflammation enhance each other to

drive chronic progression of neurodegeneration

19

. Within Lewy bodies, α-synuclein reportedly

undergoes post-translational modifications such as phosphorylation and ubiquitination. In
particular, α-synuclein phosphorylation at residue S129 (pS129) has received much attention in
recent years, since several studies reported that patients with synucleinopathies exhibit high
accumulation of pS129 α-synuclein (reviewed in

20

). Phosphorylation of α-synuclein at S129

promotes the formation of soluble oligomeric α-synuclein that correlates with neurotoxicity

21

.

However, the mechanisms by which pS129 regulates α-synuclein function, and whether pS129
negatively or positively contributes to PD pathogenesis are still being investigated.
Secondly, environmental factors, such as toxins and lifestyle, are also related to
neuroinflammation. Factors associated with the increased risk of developing PD are pesticides,
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trichloroethylene (an industrial solvent), methamphetamine, well-water, rural living, farming
occupation, beta-blocker use, history of anxiety or depression, traumatic brain injury, and diet
(reviewed in 22 and 23).
Thirdly, the process of PD onset and progression is likely to involve apoptosis and
oxidative stress, mitochondrial dysfunction, and altered protein processing, which all appear to
be involved in neuroinflammation (for review see 24).
Fourthly, compared to normal controls, the brains of PD patients exhibit significant
increases in the numbers of activated microglia, astrocytes and T lymphocytes, as well as in the
expression of cyclooxygenase (COX)-2 and other pro-inflammatory mediators 5;25-29.
Neuroinflammation involves prolonged gliosis of microglia and astrocytes and
infiltration of other immune cells such as T lymphocytes and peripheral dendritic cells into the
brain by crossing a compromised blood brain barrier (BBB), thus perpetuating the immune
response. Upon activation, both microglia and astrocytes undergo morphological changes. In
addition, activated microglia and astrocytes release a broad range of inflammatory mediators that
include eicosanoids, cytokines, chemokines, reactive free radicals and proteases. Some of these
mediators are neuroprotective while others are neurotoxic, supporting the notion that
neuroinflammation is a double-edged sword playing both detrimental and beneficial roles
depending on the circumstances 30;31.
Microglia - Microglia are distributed across all major brain regions, and are densely
populated in the SNpc, taking up 12% of the local cell population

32

. During development and

aging, microglia carry out diverse functions in the normal and disease states of the CNS. Recent
studies have expanded our understanding of the “resting-state” of microglia, as being actively
involved in neuronal connectivity and synaptic plasticity (for review see

5

33

). Nevertheless,

microglia are commonly known for the initiation of inflammation in response to CNS injury,
infection, and pathology. Some studies suggest that activated microglia are beneficial to DA
neurons by releasing neurotrophic factors

34;35

. However, most findings support that activated

microglia are harmful to DA neurons in the SNpc, as they release proinflammatory
prostaglandins, cytokines, and chemokines, in addition to expressing high levels of COX-2 36;37.
Astrocytes - Beyond the typical housekeeping role of maintaining the homeostatic
environment for neuronal activity, astrocytes play other critical roles such as direct participation
in synaptic transmission and neurovasculature modulation. Additionally, activation of astrocytes
can be induced by brain injuries due to infection, trauma, ischemia or neurodegeneration and
lead to scar formation in severe cases 38. During astrogliosis, astrocytes undergo changes in their
morphology and molecular profiles. Reports on the extent of astrogliosis in the SN of PD brains
are somewhat mixed (reviewed in

39

), but findings of massive reactive astrocytes within the

SNpc indicates a robust inflammatory state.
Astrocytes are activated via their own intracellular mechanism, as well as by molecules
released as results of microglia activation, leukocyte infiltration, neuronal degeneration and
endothelial activation in response to injuries. Once astrocyte activation is triggered, it can be
sustained by endothelin, growth factors and inflammatory molecules, leading to activation of
inflammatory pathways including up-regulation of COX-2 and its derivatives

40

. Our

understanding of reactive astrocyte function is still limited. Whether activation of astrocytes
serves neuroprotective roles or contributes to chronic inflammation is uncertain, as it depends on
specific molecular signaling cascades being up- or down- regulated. Modulation of diverse
molecules by reactive astrocytes varies with the type of astrogliosis trigger and with time after
insult

38

. Ongoing efforts are being made to characterize harmful and protective reactive
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astrocytes as both types are induced by neuroinflammation. According to a study with
lipopolysaccharide (LPS)-treated rodent postnatal cell culture and mice

41

, activated microglia

induce the neurotoxic type of reactive astrocytes that lost many normal astrocytic functions, and
not the beneficial type of astrocytes in which many neurotrophic factors are upregulated. The
number of the neurotoxic C3 (complement component 3) expressing reactive astrocytes is three
times higher in the SN of PD brains 41.
Recruitment of immune cells – The brain has long been classified as an “immune
privileged” organ, separated from the periphery by the BBB. However, surveillance by the
immune system is now recognized as a routine occurrence in the brain, even under healthy
normal conditions. Changes in the numbers of immune cells such as leukocytes, T and B
lymphocytes, monocytes, macrophages and dendritic cells, in the CNS require further
investigation. However, it is certain that immune cells cross the BBB during inflammatory
challenges (reviewed in 42).
The BBB of PD brains is compromised and exhibits hyperpermeability

43

, allowing

increased infiltration of peripheral immune cells into the brain. PD postmortem studies revealed
increased infiltration of CD4+ and CD8+ T cells in SNpc

28

. Studies with 6-hydroxydopamine

(6-OHDA), 1-methyl-1,2,3,6-tetrahydropiridine (MPTP) and LPS animal models replicated these
findings on the integrity of the BBB and immune cell infiltrations

28;44;45

. Emerging evidence

supports that recruitment of peripheral immune cells, particularly T lymphocytes, contributes to
PD pathology, but the mechanism of infiltration and its role in PD pathogenesis remains elusive
(reviewed in 46;47).
COX-2 – Compared to age-matched controls, PD brains exhibit higher expression of
COX-2 in the SNpc 48. In addition, epidemiological studies indicate an inverse relation between
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the use of certain non-steroidal anti-inflammatory drugs (NSAIDs) that inhibit cyclooxygenases
and the risk for developing PD. Although there are conflicting results in the relation between
NSAID use and PD, the evidence for lowering the risk of PD is strongest for the use of ibuprofen
5;49

. However, clinical studies have not consistently replicated the efficacy of NSAIDs, most

likely because current NSAIDs have serious side effects and poorly cross the BBB 5. An
improved understanding of the shared and specific mechanisms by which NSAIDs inhibit
cyclooxygenases and reduce prostaglandin levels, is required to effectively target the
cyclooxygenase pathway to treat PD.
1.a.3. PD animal models
There is a general consensus on the impact of certain environmental and genetic factors
on PD pathology. Therefore, administration of toxins such as 6-OHDA, MPTP, rotenone, and
paraquat, or genetic manipulation of α-synuclein, pink1, parkin, and lrrk2 genes have been used
to model PD in animals. These models have contributed significantly to a better understanding of
PD pathology, however none captures all of the PD hallmarks. There is still a need for improved
models that mimic PD pathology, especially the progressive nature of DA neurodegeneration in
the SNpc. Animal models that depict progressive development of PD, will advance PD diagnosis
and prognosis.
Progressive models of PD are required, to capture earlier stages of PD pathology with
less severe DA neurodegeneration. Animal models of PD should display DA neurodegeneration
and motor deficits similar to those exhibited by PD patients
52;53

50;51

, but this is often not the case

. For instance, PD models based on genetic risk factors, such as mutations in parkin, pink1

and lrrk2, show little or no nigrostriatal degeneration and motor symptoms. Several
pharmacological PD models, such as 6-OHDA, MPTP, paraquat and rotenone, exhibit motor
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symptoms caused by rapid and severe degeneration of the nigrostriatal pathway, i.e. reaching 90%
degeneration in a few days 53. In other PD models, changes in toxin dosage, schedule, route, and
injection site, are applied to mimic the progressive nature of PD

54

. For example, one striatal

injection of 6-OHDA (20g / 3µL) can induce 30% DA neuronal loss by 14 days, and 50% by 28
days post-injection

55

. Repeated 6-OHDA (100 µg / 4µL) intraventricular administration via an

implanted cannula also induced progressive (up to 60%) DA neuronal degeneration 56. In the 6OHDA model, the DA neurons lack the PD hallmark Lewy bodies, despite exhibiting DA
neurodegeneration 53.
Repeated weekly intraperitoneal (i.p.) injections of MPTP (32 mg / kg) can also generate
a progressive model of PD 57. Lewy body formation was detected in the MPTP model, depending
on the mode of toxin administration

58

. For example, when low MPTP concentrations are

delivered continuously via an implanted osmotic minipump over 30 days, mice exhibited Lewylike aggregates attributed to chronic impairment of the ubiquitin-proteasome pathway. In contrast,
upon intermittent MPTP i.p. injections, mice lacked ubiquitin and α-synuclein inclusions,
attributed to rapid recovery of the ubiquitin-proteasome pathway

59

. In monkeys, Lewy-like

structures were detected upon chronic administration of MPTP (reviewed in 60).
Vulnerability to MPTP varies among species and strains, as systemic administration of
MPTP results in loss of DA neurons in mice and monkeys, but not in rats

61;62

. Rat resistance to

MPTP toxicity is attributed to high levels of monoamine oxidase (MAO) present in their
microvessels at the BBB. Since MPTP is lipophilic, it can cross the BBB. In the brain, MPTP
exerts its neurotoxic effect once it is metabolized by MAO to 1-methyl-4-phenylpyridine
(MPP+), which is selectively taken up by DA neurons. MPP+ is not lipophilic and if generated
outside of the brain it poorly crosses the BBB, as in the case of rats due to their high MAO levels
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at BBB microvessels, (reviewed in

63

). The neurotoxic effects of systemically administered

MPTP in different species and strains, is thus affected by the rate and site of MPTP conversion to
MPP+ 64.
New genetic and toxin models are being created to mimic the progressive nature of PD,
such as in the case of the MitoPark mouse and the use of Beta-sitosterol beta-D-glucoside
(BSSG), a toxin found in cycad flour. In MitoPark transgenic mice, Tfam, a gene essential for
mitochondrial DNA maintenance, is selectively inactivated in DA neurons 65. BSSG mixed into
food pellets is administered to rats to induce PD pathology

66

. Further characterization and

validation of these new progressive PD models are necessary.
In relation to the etiology of human PD, genetic factors only account for about 10% of
PD cases 67, and most toxins commonly used in animal models have little to do with human PD
etiology. There is no rotenone PD related incidence reported, and only 95 paraquat-linked PD
cases were described to date

58;68

. MPTP-induced PD outbreaks were limited to certain

geographical regions during the 1970s and 1980s. 6-OHDA was first reported in 1968 to deplete
noradrenaline (NA) and DA in rat brains 58, before its use in PD animal models.
In addition to genetic and environmental factors, aging is also a major risk factor for PD,
as most PD cases are reported in people over 60. The normal aging brain exhibits increased
neuroinflammation

69;70

,

and

post-mortem

neuroinflammation is involved in PD pathology

studies
19;25;27;29

with

PD

(reviewed in

brains
26;48

confirm

that

). The LPS-mediated

model of PD is often used to address the relationship between neuroinflammation and the
pathogenesis of PD. LPS is a lipoglycan component of the Gram-negative bacterial outer wall
and elicits a strong immune reaction in animals. Single LPS systemic administration to adult
mice causes progressive dopaminergic neuronal loss 71. However, because microglia are present
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in a variety of brain regions, activation of microglia and the subsequent proinflammatory
response induced by LPS are not specific to the SN and involve other regions of the brain. To
overcome this drawback, LPS is also administered intracranially into the SN, striatum or globus
pallidus. These later LPS models show microglia activation, dopaminergic neuronal loss with no
damage to GABAergic or serotoninergic neurons, enhanced α-synuclein nitration, increased
level of proinflammatory cytokines (IL-1β, TNF-α, IL-6 and NO), and motor deficits (reviewed
in

72

). A significant finding is that the LPS-induced pathological changes were more severe in

middle-aged (16 month old) rats than in young (3 month old) rats, strongly confirming that aging
is a critical risk factor in the development of PD 73. One of the shortcomings of this model is that
when injected intracranially, the LPS effect is acute causing nigral DA neuronal loss within 24
hours and persisting up to 30 days, thus not mimicking the progressive nature of PD pathology 74.
Despite all of the described limitations, PD animal models underline microglia as
initiators of PD pathology. For instance, microglia activation precedes neuronal loss in double
mutant human α-synuclein expressing transgenic mice, 6-OHDA and rotenone models (reviewed
in 75). PD animal models of MPTP and LPS also report microglia activation (for review see 76).
The impact of microglia in PD pathology validated in animal models, is in agreement with
clinical studies of PET-imaging showing that neuroinflammation is elevated in PD patients 77.
An important mediator of neuroinflammation is the cyclooxygenase (COX) pathway

78

,

which is a major contributor to neurodegeneration in PD 48. Polymorphisms in the cox-2 gene are
associated with PD 79;80. In addition, involvement of the COX pathway is clearly demonstrated in
existing genetic and toxin models of PD. Both idiopathic and lrrk2-associated PD patient
fibroblasts exhibit increases in COX-2 mRNA levels, and this effect is decreased upon lrrk2
knockdown

81

. COX-2 expression is also significantly increased in the striatum of MPTP-
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injected C57BL/6 mice 82, in the midbrain of rotenone-treated Sprague Dawley rats 83, and in the
striatum of unilateral 6-OHDA-lesioned Wistar rats 84. Together, these findings support that the
COX pathway has an impact in PD pathology.
Epidemiological studies with NSAIDs, which are COX inhibitors, support the role of the
COX pathway in PD. The first compelling epidemiological study showing the PD therapeutic
benefits of NSAIDs was reported in 2003 from two cohorts of 98,845 women and 44,057 men of
the Nurses' Health Study and the Health Professional Follow-up studies, respectively

85

. Non-

aspirin NSAIDs lowered the risk of PD by 45%, and two-or-more daily tablets of aspirin yielded
a similar effect

85

. In a later study of two cohorts of 98,892 women and 37,305 men, ibuprofen

(1-2, 3-5 and 6+ tablets per week) was shown to lower the risk for PD by 15%, 60% and 45%
respectively 49. When other six published studies of NSAIDs use with PD were pooled together,
ibuprofen users had approximately 30% less risk of developing PD 49.
In contrast, clinical studies have not replicated the benefit of using NSAIDs to reduce PD
risk and pathology. There is thus a critical need to investigate the role of the products and factors
of the prostaglandin pathway downstream from COX, in PD neurodegeneration. To address this
need, we previously developed a mouse model of neuroinflammation induced by prostaglandin
J2 (PGJ2) that exhibits PD-like pathology 86;87. Investigating the role played by the downstream
prostaglandin products of cyclooxygenase pathway may lead to the development of more
specific and effective strategies to prevent, treat and assess PD pathology.
1.b.

PROSTAGLANDIN

J2

AS

AN

ENDOGENOUS

PRODUCT

OF

THE

CYCLOOXYGENASE PATHWAY
Cyclooxygenases are key enzymes in the conversion of arachidonic acid to
prostaglandins. In many cell types, COX-1 is constitutively expressed under normal
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physiological conditions and COX-2 is induced upon injury. In contrast to the periphery, COX-2
is also constitutively expressed in the CNS
vasodilation

89;90

88

, playing a role in synaptic function and neuro-

. However, physiological imbalances caused by CNS injury lead to up-

regulation of COX-2 expression and activity 91. The finding that COX-2 is highly up-regulated
in SNpc in postmortem PD brains 48 indicates that the COX pathway is a major component of the
neuropathology and progression of PD.
During neuroinflammation, increased expression of COX-2 occurs not only in neurons
but also in astrocytes and microglia

92

. Many studies support that COX-2 contributes to

neurodegeneration in PD, and that NSAIDs may be a viable treatment option

49;93-96

. However,

the role played by the prostaglandin products of cyclooxygenases in the neurodegenerative
process is not clearly defined. The effectiveness of NSAIDs could be compromised because
these drugs block the generation of all prostaglandin products of cyclooxygenases, including
those that are neuroprotective and those that are neurotoxic.
1. b.1. Cyclooxygenase pathway with a focus on PGD2
Cyclooxygenases catalyze the conversion of arachidonic acid into prostaglandin H2
(PGH2). Prostaglandin specific synthases, then convert PGH2 into multiple prostaglandins (PGs),
some being neuroprotective and others neurotoxic
prostaglandin in the rodent brain

3;100

97-99

. PGD2 is the most abundant

and its level increases under pathological conditions such

as in models of experimental seizures and ischemia 101. Depending on the circumstances, PGD2
may play pro-inflammatory or anti-inflammatory roles 102.
PGD2 is synthesized by two types of Prostaglandin D synthases (PGDS): hematopoieticPGDS (H-PGDS) and lipocalin-PGDS (L-PGDS). Although these two enzymes catalyze the
same type of reaction, they differ in their evolutionary origin, amino acid sequence, tertiary
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structure, and cellular as well as tissue distribution

103;104

PGD2 synthesis in peripheral immune and inflammatory cells

105

.

H-PGDS is involved in

. L-PGDS was first discovered

in the rat brain 106;107 and is predominantly found in the CNS, male genital organs, heart, kidneys
and lungs

103

. In the brain, L-PGDS together with PGD2, promotes the recruitment and

morphological transformation of microglia and astrocytes during gliosis

108

. L-PGDS was also

identified as a major apoptotic factor in the plasma of Alzheimer's disease (AD) patients 109.
The effects of PGD2 are mediated via two types of G protein-coupled receptors (GPCRs),
DP1 and DP2, to which PGD2 binds with similar affinities in the approximate rages of 4 – 17nM
110;111

. Activation of DP1 and DP2 receptors leads to opposite effects on cAMP production. The

DP1 receptor is coupled to a Gs-type G protein, therefore its activation leads to increased
intracellular cAMP as well as neuronal protection

101;112

. In contrast, DP2 receptor activation

leads to Gi-mediated inhibition of cAMP production, increases in intracellular calcium, and
neuronal cell death (reviewed in 1). Due to their low calcium buffering capacity 6, SNpc neurons
could be exceptionally vulnerable to the deleterious effects of DP2 activation.
The major toxic effects of PGD2 are not attributed to its DP receptor activation. Instead,
they are mediated by PGD2 spontaneous dehydration to the J-series prostaglandins, PGJ2 and its
metabolites, ∆12-PGJ2 and 15-deoxy-∆12,14-PGJ2 (15d-PGJ2)

113

. PGJ2 binds to the DP2

receptor with an affinity similar to PGD2, but exhibits a much lower affinity for DP1 (reviewed
in 1). This contrasting binding affinity of PGJ2 to the two DP receptors could be considered one
of the mechanisms by which PGJ2 induces its neurotoxic effects. PGJ2 derivatives also activate
PPARγ nuclear receptors in microglia and astrocytes, which mediate their anti-inflammatory
effects

114;115

. Nonetheless, the expression of PPARγ nuclear receptors are much higher in

neurons than in microglia and astrocytes

116

. Additionally, the affinity of prostaglandins for
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GPCRs such as the DP1 and DP2 receptors is two to three orders of magnitude higher than for
PPARγ, shown to be at the µM range (reviewed in

117;118

). These data suggest that the effect of

PGJ2 via PPARγ receptors is more likely greater on neurons than on glia. In addition, the
neuroprotective and anti-inflammatory effects of PGJ2 via PPARγ are more likely to be
dampened by its neurotoxic effect via DP2 on neurons and proinflammatory effect via DP1 on
microglia.
15-hydroxyprostaglandin dehydrogenase (15-PGDH) is a key prostaglandin-degrading
enzyme that negatively regulates PG levels

119

. 15-PGDH is ubiquitously expressed in

mammalian tissues and can metabolize a variety of PGs, such as PGE1, PGE2, PGF1, PGF2,
PGI2, and 6-keto-PGF1. Although PGD2 is a poor substrate for 15-PGDH

119

, PGD2 is

converted by 15-PGDH into 15-oxo-PGD2, which gives rise to the inactive form 13,14-dihydro15-oxo-PGD2 120. 15-PGDH expression and activity can be stimulated by NSAIDs, but the level
of stimulation varies with NSAID type and mechanism of action, as well as cell type. The
mechanisms by which NSAIDs stimulate 15-PGDH are not yet fully established 121;122.
1.b.2. PGJ2 as an endogenous mediator of inflammation
Prostaglandins are important regulators of neuroinflammatory pathways. Upon brain
injury, activated microglia and astrocytes release large quantities of prostaglandins such as
PGD2, PGE2, and J-series of prostaglandins, as do neurons to a lesser degree (reviewed in 1).
PGJ2 is derived from PGD2 (Fig. 1.1A) which is the most abundant prostaglandin in the
brain and undergoes most upregulation during pathological events (Fig. 1.1D). The half-life of
PGD2 is estimated to be ~1.1 minutes in the brain, and J2 prostaglandins are formed from the
highly unstable PGD2 through non-enzymatic spontaneous dehydration. When tested in neuronal
cultures, among the four prostaglandins PGA1, D2, E2 and J2, PGJ2 was shown to be the most
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neurotoxic, whereas PGE2 was the least neurotoxic 123.

1

2

Fig. 1.1. (A) PGJ2 and its metabolites . (B) Receptor-dependent actions of PGJ2 . (C)
1
Receptor-independent action of 15d-PGJ2 . See text for explanation. (D) Concentrations of
different prostaglandins in brain cortical tissue of young rats (16-18 days postnatal) at 5min
post resuscitation after being subjected to asphyxia cardiac arrest for 12min to induce brain
3
ischemia . Prostaglandin levels were measured by UPLC-MS/MS.

During neuroinflammation, in vivo concentrations of free J-series prostaglandins can rise
from less than 10nM to approximately 270nM, as detected in the brain of a rat model of stroke
124

. Extracellularly, PGJ2 exerts its effects by binding to the DP2 receptor (Fig. 1.1B). However,

PGJ2 can re-enter cells by diffusion across the plasma membrane, or via a prostaglandin
transporter. Intracellularly, PGJ2 can bind to the nuclear receptor PPARγ, or can bind covalently
to proteins as discussed below.
Unlike other prostaglandins, PGJ2 and its metabolites have a cyclopentenone ring with
reactive α,β-unsaturated carbonyl groups

125

. These highly reactive carbonyl groups mediate the

formation of covalent Michael adducts (Fig. 1.1C) with free sulfhydryls in cysteine residues in
glutathione and cellular proteins. Due to its ability to form Michael adducts, measurements of
local cellular and intracellular PGJ2 levels may not reflect its full concentration during
neuroinflammation. Covalent modification of cysteine residues in proteins by electrophilic
compounds such as PGJ2 and its metabolites, may induce neuroprotection or neurotoxicity
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125

.

While cysteine residues are components of most proteins, not all cysteine residues are
susceptible to modification by electrophilic prostaglandins
proteins in human embryonic kidney cells (HEK-293)

127

126

. For example, out of hundreds of

, 15d-PGJ2 forms covalent Michael

adducts with only 10% of proteins that contain reactive thiols, suggesting a high degree of
specificity 128. In order to understand the full effect and the mechanisms of action of PGJ2 and its
metabolites, it is essential to identify the target proteins covalently modified by these
electrophiles. A recent proteomic analysis of human aortic endothelial cells revealed 358
proteins covalently modified by 15d-PGJ2

129

. Moreover, proteomic analysis identified 11

plasma membrane proteins from rat cortical neurons, as targets of 15d-PGJ2 Michael addition 130.
These proteins include glycolytic enzymes [pyruvate kinase M1(PKM1), Enolase 1 and 2 and
glyceraldehyde 3-phosphate dehydrogenase (GAPDH)], molecular chaperones [heat shock
protein 8 (Hsp8) and T-complex protein 1 subunit α (TCP1α)], cytoskeletal proteins [Internexin
α, Tubulin β2b, glial fibrillary acidic protein (GFAP), type I cytoskeletal keratin 20 (CK20),
Actin β, and F-actin-capping protein subunit α-2 (CapZα2)], and these neuronal proteins (except
CK20) and astrocyte-exclusive GFAP are reportedly associated with amyloid plaques and
neurofibrillary tangles, which are hallmarks of AD 130.
One of the principal effects of PGJ2 is to impair the ubiquitin/proteasome pathway (UPP)
by interfering with the 26S proteasome assembly 131-135, and also by inhibiting de-ubiquitinating
enzymes such as UCH-L1

123;131;136

, one of the most abundant neuronal protein

123;135;137

.

Therefore, PGJ2 triggers the accumulation and aggregation of ubiquitinated proteins and induces
apoptosis (reviewed in 1), both of which are hallmarks of a variety of neurodegenerative
disorders including PD.
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Finally, PGJ2 up-regulates COX-2 leading to a positive
feedback loop that could contribute to its chronic long term
effects

138;139

(Fig. 1.2). Understanding the self-sustaining cycle

of neuroinflammatory processes involving activated microglia
and astrocytes is critical to prevent/ameliorate the development
of neurodegeneration. The potential long term effects of PGJ2
present a novel view on the role of chronic neuroinflammation
in PD, induced by products of the COX pathway. Since PGJ2
up-regulates the expression of COX-2 138, PGJ2 has potential to
initiate various deleterious cascades leading to self-sustained
progressive neurodegeneration.
Drugs that can slow or reverse PD pathology are not yet
available, rendering NSAIDs the only approved drugs that can
decrease the risk and/or delay the onset of PD, potentially by

Fig. 1.2.
PGJ2 and its
metabolites are released from
activated
microglia
and
astrocytes
during
neuroinflammation,
which
could transition from acute to
chronic state via a positive
feedback loop between PGJ2
1
and COX-2. Adopted from .

preventing cyclooxygenases from synthesizing prostaglandins. However, NSAIDs yielded mixed
results in clinical trials due to their serious side effects including bleeding and ulcers

140

. The

need for anti-inflammatory drugs with fewer side effects may be met by investigating the effects
of potentially neurotoxic prostaglandin, downstream of cyclooxygenase. However, there are no
rodent models that address the potential of prostaglandins to induce PD pathology, other than our
previously established PGJ2 mouse model

86;87

. In this mouse model, nigral/striatal

microinfusion of PGJ2 into adult (12 week old) FVB male mice led to: (a) a dose-dependent loss
of DA neurons in the SNpc with little effect on GABAergic interneurons in SNpr; (b) activation
of astrocytes and microglia; (c) neuronal Lewy-like body formation; and (d) impaired gait and

18

balance similar to PD motor deficits. This PGJ2-induced mouse model can be used to test
therapeutic strategies that prevent neurotoxicity induced by products of the COX-pathway,
downstream of the cyclooxygenases.
1.c. ADVANTAGES OF DEVELOPING A RAT MODEL OF NEUROINFLAMMATION
THAT DEVELOPS PARKINSONIAN-LIKE PATHOLOGY
The unclear etiology of PD is a major obstacles and makes it challenging to create animal
models that precisely resemble PD pathology and the progressive nature of its development

141

.

Moreover, the development of a neuroprotective intervention for PD is hindered by the lack of
validated biomarkers. Evaluating new therapies in patients at advanced stage of pathology is
challenging due to the confounding effects of pre-prescribed treatments and difficulty in
choosing matching control groups. Therefore, identifying biomarkers would improve diagnostic
certainty, and identification of appropriate patients for clinical trials, and could also be used as an
objective measure of treatment efficacy 142. These issues emphasize the need for more effective
preclinical animal models than the ones currently available. The availability of new and
improved models would advance the understanding of the heterogeneity of PD pathology
throughout the disease progression and the development of better evaluation means of
diagnostics and therapeutics.
So far no definitive biomarkers have been identified for PD. However, since its
introduction in the 1950s, positron emission tomography (PET) brain scanning has improved
diagnosis and assessment of treatment for neurological diseases such as PD (reviewed in

143

).

PET can be used to characterize biological and disease processes in vivo by measuring the
quantitative distribution of imaging agents labeled with positron-emitting nucleotides. Over the
years, PET imaging resolution has improved and the number of available radiotracers has

19

increased. The importance of animal model research prompted the use of small-animal
microPET (µPET) systems specifically designed for small animals such as rats and mice.
In order to provide details of the structures of interest with accurate quantification that are
comparable to the levels provided by human studies, µPET requires a system that has a spatial
resolution that is 15 times greater for mice and 6 times greater for rats than human PET systems
144

. However, compared to the 5 mm resolution of a typical human PET system, the spatial

resolution of a commercial µPET scanner is only approximately 1 mm. The 1 mm spatial
resolution is just enough to meet the requirement for rat imaging, but is not optimal for mouse
imaging which requires 0.4 mm spatial resolution

144;145

. Current capabilities of µPET systems

do not allow identification of individual cells. Thus, pathological findings from µPET studies at
the cellular-level need to be supported by immunohistochemistry

146

. Nonetheless, µPET has

significant merit in studying the biological process in a single organism in vivo providing for
longitudinal observations.
Besides the size advantage for µPET imaging and surgical procedures, rat models are
superior to mouse models for human diseases, because rat physiology is easier to monitor and is
more similar to that of human diseases than mouse physiology. In addition, for neuroscience
research, rats have an edge over mice because rats are able to perform a wider range of cognitive
tests, and are less prone to get stressed by handlers

147;148

. Additionally, although rats and mice

have an overall identical brain anatomy, several major important differences in rat brains have
been reported over the years. These differences include the distribution of a subtype of serotonin
receptor which is involved in mood regulation, the expression of LRRK2 which is known to be
linked to PD, and the rate of neurogenesis in the hippocampus (reviewed in 148).
Based on all of these considerations, we decided to develop a rat model of
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neuroinflammation by microinjecting PGJ2 into the SNpc to induce PD-like pathology, such as
motor deficits correlated with progressive DA neuronal loss in the SNpc, activation of microglia
and astrocytes assessed in vivo with µPET imaging and in vitro by immunohistochemistry, and
the accumulation of ubiquitinated proteins and α-synuclein containing aggregates. In order to
address potential mechanisms by which PGJ2 induces toxicity in the rat model of
neuroinflammation, we characterized (for the first time ever) the distribution and levels of
downstream factors of the COX pathway: COX-2, L-PGDS, DP2 receptor and 15-PGDH. These
factors are highly relevant to neuroinflammation in PD as described in detail above.
The PGJ2 rat model of neuroinflammation that we developed is highly relevant to the
etiology of PD because PGJ2 is an endogenous product of COX-2, which is highly upregulated
in PD brains. The PGJ2 rat model exhibits a wide range of pathological and behavioral features
collectively shown in other established PD animal models which involve COX-2 upregulation.
The progressive nature of PD-like pathology exhibited in the PGJ2 rat model spans over 8 weeks,
much longer than ~30 days shown in MPTP and 6-OHDA animal models for PD

54-57

, and is

highly advantageous in exploring potential therapeutics and biomarkers. Investigations into the
prostaglandin D2/J2 pathway downstream of cyclooxygenases in the PGJ2 rat model could
discover novel therapeutic targets to protect neurons exposed to chronically activated glia.
Future studies using the PGJ2-induced rat model for in vivo detection of early stages of
neuroinflammation with µPET imaging, will provide a means to assess an important aspect of
neuroinflammation in PD and potentially identify the optimal time window for therapeutic
intervention. In addition, the newly established rat model can be used to assess the efficacy of
neuroprotective or neurorestorative therapeutics for PD patients in a non-invasive continuous
manner.
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CHAPTER II

Prostaglandin D2/J2 pathway in a rat model of neuroinflammation displaying progressive
parkinsonian-like pathology: therapeutic potential of DP2 receptor and L-prostaglandin D
synthase

Chuhyon Corwin

Department of Biology,
Hunter College of the City University of New York,
New York, New York 10065
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2.1. ABSTRACT
Prostaglandins are products of the cyclooxygenase (COX) pathway, which is implicated
in the pathogenesis of Parkinson’s disease (PD). However, limited knowledge is available on the
roles and mechanisms by which prostaglandins contribute to PD neurodegeneration in vivo. To
address this gap, we established a rat model of neuroinflammation induced by the highly
neurotoxic prostaglandin J2 (PGJ2), which is spontaneously derived from PGD2. PGD2 is the
most abundant prostaglandin in the brain and it increases the most under pathological conditions.
Unilateral nigral PGJ2-microinfusions in the rats were sufficient to induce progressive PD-like
pathology. Concomitant with dopaminergic neuronal loss in the SN pars compacta (SNpc), the
PGJ2-treated rats exhibited progressive microglia and astrocyte activation, and motor deficits.
We investigated the impact of PGJ2-treatment on key factors of the prostaglandin D2/J2
pathway, including: COX-2, lipocalin-type PGD2 synthase (L-PGDS), PGD2/J2 receptor 2
(DP2), and 15-hydroxyprostaglandin dehydrogenase (15-PGDH), a PG-inactivating enzyme. In
SNpc DA neurons, COX-2, L-PGDS, and 15-PGDH levels increased significantly in PGJ2treated rats compared to controls. DA neuronal DP2 receptor levels were similar in all rat groups.
In microglia, COX-2 and L-PGDS increased upon PGJ2-treatment. Microglial DP2 receptors
were almost absent in control and PGJ2-treated rats, while 15-PGDH levels were comparable in
all rat groups. We also detected 15-PGDH in SNpc oligodendrocytes. Notably, ibuprofen
prevented most of the PGJ2-induced PD-like pathology. Overall, our studies establish that the
PGJ2-induced rat model mimics, to a certain extent and in a short time frame, the progressive
nature of PD pathology. Moreover, we address, to our knowledge for the first time, the potential
of targeting factors downstream of cyclooxygenases to improve treatment outcomes. Based on
our data we propose that DP2 receptor antagonists and L-PGDS inhibitors are novel putative
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therapeutics that may bypass the adverse side effects of cyclooxygenase inhibitors, and
ultimately diminish neuroinflammation-mediated neurodegeneration in PD.
2.2. INTRODUCTION
Neuroinflammation is a defense response activated upon CNS injury to acutely initiate
repair mechanisms, while chronic neuroinflammation can exacerbate, spread and prolong CNS
injury. It is well accepted that chronic neuroinflammation plays a central role in Parkinson
disease (PD) 149-154. Critical to neuroinflammation is cyclooxygenase-2 (COX-2), which is highly
induced in PD and negatively affects neuronal function 48;112;155-157.
As far as we know, there are no models of PD that utilize endogenous products of
cyclooxygenases to mimic the pathology and motor deficits of PD 153, besides our recent studies
with mice 86;87. PGD2 is the most abundant prostaglandin in the brain 3;100;102;158, and the one that
rises the most under pathological conditions

101

. PGD2 is highly unstable (estimated brain half-

life of 1.1 min), leading to spontaneous non-enzymatic formation of PGJ2

113

. Our rationale for

using PGJ2 to establish a rat model of neuroinflammation that develops progressive
parkinsonian-like pathology, is that PGJ2 is highly neurotoxic compared to PGD2 and PGE2 123.
In contrast to PGD2 and PGE2, PGJ2 and its metabolite 15d-PGJ2 bind covalently to proteins
through their α,β-unsaturated carbonyl groups

159

. In addition, the J2 prostaglandins are uptaken

by cells via a carrier-mediated active transport, ending up in the cytoplasm and nucleus 160. This
endocytic transport is unique to J2 prostaglandins, as it does not apply to PGD2 and E2 160.
In rodents, the brain levels of PGJ2 are highly induced upon stroke (cerebral ischemia)
3;124;136

and traumatic brain injury (TBI)

161;162

, reaching concentrations

3

that are known to be

neurotoxic. Moreover, both stroke and TBI increase the long-term risk for PD 163-167. We recently
showed that PGJ2 induces PD-like neuropathology in mice
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86;87

. Unilateral nigral microinfusion

of PGJ2 into mice induced a selective loss of dopaminergic (DA) neurons in the substantia nigra
pars compacta (SNpc), while sparing DA neurons in the ventral tegmental area (VTA) and
GABAergic neurons in the SN pars reticulata (SNpr). Furthermore, PGJ2 microinfusions caused
the accumulation of ubiquitinated proteins, microglia activation, as well as motor deficits in the
mice.
Rat models offer many advantages over mouse models for human disease

147

. Rats share

90% of their genome with humans, and most currently identified disease-linked human genes
have equivalent ones within the rat genome 168. Compared to the mouse, rat physiology is easier
to monitor and closer to the human condition, and rats are more intelligent and capable of
learning a broader variety of tasks

147

. Rats are also larger than mice and thus better suited for

surgeries, and for use in the small-animal PET system (µPET) in preclinical research and drug
development, which requires high spatial resolution. This is particularly important in the CNS.
Based on all of these advantages, we focused our studies on developing a PGJ2-induced rat
model of neuroinflammation relevant to PD.
As limited information is available on the role and mechanisms by which prostaglandins
contribute to neurodegeneration in vivo, we investigated the impact of PGJ2 microinfusions on
key factors of the prostaglandin D2/J2 pathway, including: COX-2, lipocalin-type PGD synthase
(L-PGDS), PGD2/J2 receptor 2 (DP2), and 15-hydroxyprostaglandin dehydrogenase (15-PGDH),
a PG-inactivating enzyme. L-PGDS converts PGH2 to PGD2, and is found in the CNS, male
genital organs, heart, kidneys and lungs

103

. The DP2 receptor is a Gi protein coupled receptor

that binds PGD2 and J2 with similar affinities, resulting in a decrease in cAMP and an increase
in calcium levels

169

. 15-PGDH is ubiquitously distributed in mammalian tissues, and is the key

enzyme negatively regulating prostaglandin levels
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170

. We compared the levels and cell-type

distribution (DA neurons versus microglia) of these four key factors of the prostaglandin
pathway in control (DMSO) and PGJ2-treated rats, in an effort to identify potential new targets
for therapeutic intervention downstream from cyclooxygenases, thus with fewer side effects.
In neurons, PGJ2 upregulates COX-2 138 potentially establishing a positive feedback loop
between PGJ2 and COX-2 that could promote the transition from acute to chronic
neuroinflammation. To investigate whether inhibiting cyclooxygenases diminishes the
progressive PD-like pathology induced by PGJ2, we administered ibuprofen orally with food, to
control (DMSO) and PGJ2-treated rats. Ibuprofen is a non-steroidal anti-inflammatory drug
(NSAID) that inhibits COX-1 and COX-2, thus reducing the synthesis of all prostaglandins 150;154.
Epidemiological studies support an inverse relation between the use of ibuprofen and the risk of
developing PD

49;171

conflicting results

, with the risk reduction being as much as 50%

5;172

172

. However, there are

. Clinical studies with NSAIDs have not showed a similar trend

5;173

.A

better understanding of the shared and diverse mechanism of action of NSAIDs, including
cyclooxygenase inhibition and decreased prostaglandin production, is required to more
effectively modulate the neurotoxic outcomes of neuroinflammation with fewer side effects 5.
In summary, our newly developed PGJ2-induced rat model of neuroinflammation
exhibits progressive parkinsonian-like pathology that persists over a long period of time, and that
can be diminished by administration of an NSAID such as ibuprofen. Based on our new findings,
we propose that this pre-clinical rat model induced by PGJ2 is highly valuable to identify
biomarkers and optimize therapeutics, such as DP2 receptor antagonists and L-PGDS inhibitors,
which prevent or delay the progression of PD associated with neuroinflammation.
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2.3. MATERIALS AND METHODS
Our study followed the strict recommendations in the Guide for the Care and Use of
Laboratory Animals of the National Institutes of Health (NIH). Our protocol was approved by
the Hunter College, CUNY Institutional Animal Care and Use Committee. Surgeries were
carried-out under isoflurane anesthesia, and we made all efforts to minimize animal suffering.
2.3.1. Reagents and antibodies - PGJ2 (cat. # 18500) and ibuprofen (cat. # 70280) from
Cayman Chemical (Ann Arbor, MI). PGJ2 (33.4 µg / injection) was diluted in DMSO and then
further diluted in PBS to a final DMSO concentration of 17% for PGJ2 microinfusions. The
PGJ2 solutions were freshly prepared and stored for a maximum of 2h at 4°C and in the dark. A
17% DMSO/PBS was microinfused as the vehicle control. Primary antibodies: dopaminergic
neurons [TH, tyrosine hydroxylase, 1:1000, cat.# MAB318 (mouse), Millipore (Billerica, MA)
and cat.# Ab6211 (rabbit), Abcam (Cambridge, MA)]; microglia [Iba1, 1:500, cat.# 019-19741
(rabbit), Wako (Richmond, VA) and 1:1000, cat.# ab139590 (chicken), Abcam]; astrocytes
[GFAP, 1:1000, cat.# AB5541 (chicken), Millipore]; oligodendrocytes [GST-pi, 1:200, cat.#
ab53943 (goat), Abcam]; polyubiquitinated proteins [Ub, 1:200, cat.# BML-PW8805 (mouse),
Enzo Life Sciences (Farmingdale, NY)]; phosphoS129 α-synuclein [pS129 α-syn, 1:200, cat.#
p1571-129, PhosphoSolutions (Columbia, MD)]; cyclooxygenase-2 [COX-2, 1:250, cat.#
160106 (mouse), Cayman Chemical (Ann Arbor, MI)]; prostaglandin D synthase [L-PGDS,
1:200, cat.# ab182141 (rabbit), Abcam]; prostaglandin D2 receptor [DP2, 1:1000, cat.# PA520332 (rabbit), ThermoFisher (Waltham, MA)]; 15-Hydroxyprostaglandin dehydrogenase [15PGDH, 1:500, cat.# NB200-179, Novus (Littleton, CO)]. Secondary antibodies – Alexa Fluor
568 (1:250, cat.# A11036, rabbit and cat.# A11031, mouse), Alexa Fluor 488 (1:250, cat.#
A11039, chicken) and Alexa Fluor 350 (1:250, cat.# A10039, rabbit and cat.# A10035, mouse)
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from Life Technologies (Carlsbad, CA). Vectashield mounting medium (cat# H-1000, Vector
Laboratories, Burlingame, CA).
2.3.2. Rats - Sixteen-week old Sprague Dawley male rats (N = 37; body weight: 376 g - 533 g)
were obtained from Taconic Biosciences (Hudson, NY) and Envigo (Frederick, MD). Rats were
singly housed on a 12-h light/dark cycle, maintained at 23oC and 50-70% humidity, with food
and water available ad libitum. Rats were allowed to acclimate for one week before the baseline
behavior assessment, and were 18 weeks old at the time of the first injection.
2.3.3. Surgery and microinfusions - We followed the same procedures for the rats as described
in our previous study with mice

87

. Rats received unilateral (right side) injections of vehicle

(DMSO) or PGJ2 into the SN. Briefly, at 18 weeks of age, rats were anesthetized by isoflurane
inhalation (induction 2.5%-3.5%, maintenance 2.5%) administered in 100% oxygen and placed
into a stereotaxic frame (Model 51730D, Stoelting Co., Wood Dale, IL) fitted with a gas
anesthesia mask (Model 906, David Kopf Instruments). A burr hole was drilled in the skull at
coordinates for the SNpc

174

: anterior-posterior (AP) = -5.6mm; medial-lateral (ML) = +2.0mm;

and dorsal-ventral (DV) = -8.0mm relative to the bregma. All injections were administered to the
right SN, while the contralateral (left) side served as an internal control. A two µL microinjection
Hamilton syringe (7002 KH) with a 25-gauge needle was slowly inserted into the brain and left
in place for two minutes. Thereafter, two µL of solution was infused at an injection rate of 0.2
µL/minute (Quintessential stereotaxic injector, Model 53311, Stoelting Co.). The needle was left
in place an additional three minutes to ensure total diffusion of the solution. Following injection,
the needle was slowly removed and the incision was closed with monofilament absorbable
sutures (cat. # 038729; Henry Schein, Melville, NY). After surgery, rats were removed from the
stereotaxic frame and administered a subcutaneous injection of one cc Lactated Ringer’s solution,
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given wet palatable rodent chow, and kept in a warm place to recover. Subsequent injections to
the SN were administered via the same drill hole established during the first surgical procedure.
2.3.4. Ibuprofen administration – Ibuprofen can be administered to rats twice daily for up to 80
days without adverse secondary side effects

175

. In our experiments, rats were fed ibuprofen

fortified chow (ibuprofen: ~40mg/kg body weight) ad libitum chronically starting immediately
after the first PGJ2 treatment. Ibuprofen was added to Purina 5001 Rodent Chow (800 ppm,
Research Diets, Inc., New Brunswick, NJ). Individual intake of ibuprofen was measured by daily
weighing of the given and leftover chows per animal.
2.3.5. Groups - Rats were randomly assigned to 8 groups receiving the following microinfusions
(Fig. 2.1): (1) four DMSO alone, sacrificed 4 weeks after the last injection; (2) four DMSO/PGJ2,
sacrificed 4 weeks after the last injection; (3) two DMSO alone, sacrificed 4 weeks after the last
injection; (4) two DMSO/PGJ2, sacrificed 4 weeks after the last injection; (5) two DMSO alone,
sacrificed 8 weeks after the last injection; (6) two DMSO/PGJ2, sacrificed 8 weeks after the last
injection; (7) two DMSO and fed ibuprofen, sacrificed 4 weeks after the last injection; (8) two
DMSO/PGJ2 and fed ibuprofen, sacrificed 4 weeks after the last injection. Rats in each group
received two or four unilateral DMSO or PGJ2 injections (once/week for two or four consecutive
weeks), starting at the age of 18 weeks.
2.3.6. Behavior - Rats were tested for parkinsonian-like behavior four and eight weeks after their
last injection (Fig. 2.1). We used the cylinder behavioral test that assesses spontaneous activity
and limb use asymmetry in a novel environment. This is a sensitive behavioral test used to detect
unilateral damage to the nigrostriatal pathway 176. An additional advantage of the cylinder test is
that inter-rater reliability is very high (r > 0.95) even with relatively inexperienced raters 176;177.
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Rats were placed in a transparent cylinder (11 inches in diameter and 18 inches in height)
and video-recorded for 5 – 10 minutes depending on the activity level. A mirror was placed at an
angle underneath the raised cylinder to allow the view of the back wall and the bottom of the
cylinder. To determine the extent of asymmetry, the use of the left and right forelimbs were
counted during the wall movements after a rear, and during the landings as described in 176.
Forelimb use asymmetry is determined by the preference towards the non-impaired
forelimb for weight shifting movements during spontaneous vertical exploration. These
movements along the wall and landings after a rear, were separately recorded and then averaged
for total asymmetry, to correct for variability as described in

176;177

. Each cylinder video was

scored by two raters blind to the experimental group to further reduce the variability. Their
scores were averaged and statistically analyzed.
Rodents display innate limb preference correlated to endogenous nigrostriatal DA
imbalance 178. Thus, the effect of the unilateral surgery on the behavior was measured as percent
(%) change of the forelimb use asymmetry post-surgery, compared to the baseline behavior presurgery.
2.3.7. Immunohistochemistry – After the behavior analyses, rats were anesthetized (i.p.) with
ketamine (100 mg/kg) and xylazine (5 mg/kg), and transcardially perfused with 4%
paraformaldehyde in PBS. The rat brains were removed, post-fixed overnight at 4°C, followed
by cryoprotection (30% sucrose/PBS at 4°C). Brains were sectioned in the coronal plane using a
freezing microtome at a thickness of 30µm, and sections were collected serially along the
rostrocaudal axis of the substantia nigra pars compacta (SNpc) [between -4.56mm and -6.36mm
for the SNpc; coordinates relative to bregma, as in

174

]. Tissue series (eight series for the SNpc)

were stored at 4°C in cryoprotectant (30% glycerol and ethylene glycol in PBS) until use. Each
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series was processed as free floating sections for immunohistochemical analyses as described in
86

. At the end, sections were mounted on gelatin-subbed glass slides with Vectashield. Sections

were viewed under a wide-field fluorescence microscope (Zeiss AxioImager) using a Zeiss
AxioCam MRm Rev. 3 camera connected to a motorized stage, the software AxioVision 4
module MosaiX was used to capture whole SN region mosaics (10x magnification).
Exposure time for each channel was kept consistent between sections. For each captured
image, ZVI files were loaded onto Image J (NIH, Bethesda, MD) and converted to .tif files for
use in optical density and co-localization analyses. Each channel was analyzed to a threshold
between predetermined standard deviations from the mean intensity per antibody of interest to
isolate the positive signal from each image

179

. Pixel areas meeting threshold intensity criteria

were measured in delineated SN regions.
The SNpc was delineated based on TH+ staining at 10× magnification while carefully
excluding cells within the ventral tegmental area (VTA).
For optical density (O.D.) analysis, three tissue sections per treatment group were used
for quantification. Nonspecific background density was corrected using ImageJ rolling-ball
method 180. Data was expressed as O. D. ratio from the ipsilateral SNpc over the contralateral.
2.3.8. Stereology - Unbiased stereology analysis was conducted by scorers blind to the
experimental treatments as described in 87. Total number of TH+ and Iba1+ cells were obtained
with the Zeiss AxioVision Release 4.8.2 Software unbiased stereology programming (Carl Zeiss
Group, Jena, Germany). The outline of the SNpc delineated by TH+ staining 181 was obtained at
low (10x) magnification. Within the delineated SNpc area, depending on the anterior-posterior
position of the coronal section, 5-11 sites were sampled with the optical fractionator probe. For
each brain, six SNpc sections spaced 240 µm apart were used for the analyses. Cells were
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counted at 40× magnification along the AP axis, and at predetermined intervals [x-step = 230
µm; y-step =170 µm; 39,100 µm2; frame associated area (grid size): horizontal =226.057 µm,
vertical = 168.380 µm; 38063.478 µm2]. The z-depth was set at 20 µm to allow a 5 µm guard on
the top and bottom surface of each section to avoid error in case of tissue damage. Estimated
cell numbers in the whole SNpc were used for group comparison. Dopaminergic (DA) cell
counts from the intact SNpc were similar to a previous report 182. Care was taken to ensure that
cells within the ventral tegmental area (VTA) were excluded from SN quantification.
2.3.9. Statistical analyses - All data are expressed as the mean ± SEM. Statistical analyses were
performed with GraphPad Prism 6 (GraphPad Software, San Diego, CA). A p-value < 0.05 was
considered statistically significant. For group comparisons, we performed one way analysis of
variance (ANOVA) followed by post hoc Tukey’s. One way Student's T-test was used to
compare means between two groups. Correlations between two variables were evaluated by
linear regression calculating the Pearson correlation coefficients.
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Adult Male Sprague-Dawley Rats
(18 weeks of age at the time of 1st injection)
Baseline Behavior
(Cylinder test)
PGJ2 [33.4 µg in (DMSO/PBS, 17 %)] or control (DMSO/PBS, 17 %)
Unilateral injections (2 µL) into right SNpc
4X Injections:
PGJ2 or
DMSO (Control)

2X Injections:
PGJ2 or
DMSO (Control)
+ IBP

+ 4 weeks

+ 4 weeks

+ 8 weeks

+ 4 weeks

Behavior
(n = 4-5 / gp)
IHC (n = 3 / gp)

Behavior
(n = 4 / gp)
IHC (n = 3 / gp)

Behavior
(n = 4 / gp)
IHC (n = 3 / gp)

Behavior
(n = 5-7 / gp)
IHC (n = 3 / gp)

Fig. 2.1. Schematic representation of the experimental design for the rat PGJ2-treatment.
Eighteen-week-old male Sprague Dawley male rats were microinjected into the right
substantia nigra pars compacta (SNpc) as shown. Rats received two or four microinfusions of
either DMSO (control; 17% in PBS) or PGJ2 (33.4 µg) in 2 µL DMSO/PBS at weekly intervals.
Ibuprofen (IBP) treated rats were fed IBP-mixed chow (800 ppm, ~40 mg / kg body weight)
starting the day after the first microinfusion and ending five weeks later. For all rats motor
behavior was assessed before the first injection and four weeks or eight weeks after the last
injection. Following post-injection behavioral assessment, rats were perfused intracardially
and the brains were removed for immunohistochemical analyses. n = number of rats per group
(gp).
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2.4. RESULTS
2.4.1. PGJ2 induces progressive dopaminergic neuronal loss in the rat SNpc
Following our recently established PGJ2-induced mouse model of PD-like pathology 86;87,
we investigated in vivo the progressive effects of subchronic inflammation in rats. For this
purpose, rats were administered unilateral (right side) injections of 33.4 µg / 2 µL PGJ2 to the
SNpc for two or four weeks (once per week) as depicted in Fig. 2.1. Following behavioral
analysis, the rats were sacrificed four or eight weeks post the last injection, and their brains
analyzed by immunohistochemistry.
To assess dopaminergic specific neuronal damage, we performed immunohistochemical
(IHC) staining for tyrosine hydroxylase (TH). We used the unbiased optical fractionator
stereological method and compared the ratio between the numbers of TH+ cells in the ipsilateral
SNpc over that in the contralateral side for each rat.
Rats treated with four PGJ2-microinfusions and sacrificed four weeks following the last
injection, displayed intense (74%) dopaminergic (DA) neuronal loss in the ipsilateral SNpc (Fig
2A, second panel, and 2B, right panel), compared to DMSO-treated rats. We thus decided to
reduce the number of injections to two, with the hope of detecting progressive DA neuronal loss.
Indeed, DA neuronal loss was significantly less upon two than four PGJ2 injections (Fig. 2.2A,
third and fourth panels, and 2B, right panel). Moreover, DA neuronal loss was progressive, as it
significantly [p = 0.005] intensified eight weeks compared to four weeks post-injection.
Compared to DMSO-treatment, DA neuronal loss was 32% and 20% respectively, eight and four
weeks following PGJ2-treatment. The contralateral SNpc served as the uninjected control for
each rat, and no significant differences were detected among groups (Fig. 2.2A and B, left panel).
The DA neurons in the VTA were less affected than those in the SNpc (Fig. 2.2C).
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Immunostaining for neuron-specific nuclear protein (NeuN) decreased significantly in the SNpc,
following PGJ2 administration [p = 0.002], thus corroborating that the loss in TH
immunostaining was due to the degeneration of DA neurons and not to TH depletion (Fig. 2.2D,
left panel). The decrease in NeuN+ immunoreactivity in the VTA and SNpr was either nonsignificant or less than in the SNpc (Fig. 2.2D, right panel).
2.4.2. PGJ2-treated rats develop parkinsonian-like motor deficits in a progressive manner
Clinically, PD is characterized by the development of motor deficits caused by the loss of
dopamine in the SNpc

183-185

. To determine the effect of PGJ2 treatment on motor performance,

we measured the forelimb use asymmetry with the cylinder test which is considered a sensitive
measure of the degree of unilateral nigrostriatal damage

186

. Unilateral injections into the right

SN should cause forelimb impairment in the contralateral (left) side, and encourage the use of the
ipsilateral, right-forelimb, thus reflecting a change in nigrostriatal DA. For each animal, the
percent (%) change in asymmetry between pre (baseline) and post-injection was calculated. The
mean ± SEM for each treatment group was used for the statistical analysis.
Weekly PGJ2-microinfusions induced a gradual and significant bias toward use of the
ipsilateral over the contralateral forelimb when compared to the DMSO controls (Fig. 2.3A). The
Pearson correlation coefficient indicates a significant negative correlation between ipsilateral
forelimb use and the number of ipsilateral TH+ cells in the SNpc in the PGJ2-treated rats (r2 =
0.6, p = 0.007; Fig. 2.3B, right panel). Such correlation was absent for the DMSO-treated rats (r2
= 0.047, p = 0.287; Fig. 2.3B, left panel).
These behavioral assessments together with the IHC data for the TH+ DA neurons (Fig.
2.2) strongly support that PGJ2 induces the development of PD-like pathology in a progressive
manner over the period of eight weeks post-treatment.
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Fig. 2.2. Progressive dopaminergic neuronal loss in the SNpc upon successive intranigral PGJ2
microinjections. (A) Representative coronal sections of the ventral midbrain depicting dopaminergic
neurons. TH-immunoreactivity was strong in the VTA (ventral tegmental area) and SNpc (substantia
nigra pars compacta, rectangle) of control (DMSO) rats. TH-immunoreactivity decreased in the
ipsilateral SNpc of rats receiving two (2X) or four (4X) PGJ2 injections. Dopaminergic neurons in the
VTA were less affected. Scale bar = 500 µm. (B) The extent of PGJ2-induced damage was assessed
by calculating the total number of TH+ neurons (mean ±SEM) in the SNpc using unbiased stereology
as described in Materials and Methods. No significant differences in TH+ neurons were observed in
the contralateral SNpc of the different groups of rats. TH+-immunoreactivity decreased in a gradual
manner in the ipsilateral SNpc of rats receiving two (2X) or four (4X) PGJ2 injections and at four
weeks or eight weeks post-injections of two (2X) PGJ2. (C) PGJ2-induced damage in the VTA was
measured by TH+ area (mean ±SEM). Dopaminergic neurons in the VTA were less affected than in
the SNpc. (D) Neuronal loss in the SNpc, VTA and SNpr were compared by NeuN+ area (mean
±SEM). NeuN-immunoreactivity decreased significantly in the SNpc, but less in the VTA and not
significantly in the SNpr of PGJ2-injected rats compared to controls (DMSO-treated). Black circles,
control, DMSO-treated rats; red circles, PGJ2-treated rats. Statistical significance was estimated with
One-way ANOVA (B, left) and the Student's T-test (B, right, C and D) to compare DMSO and PGJ2treated groups and between two PGJ2-treated groups. The p values in red indicate statistical
significant (<0.05) difference from DMSO-injected rats. N = 3 rats per group.
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0.6
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Fig. 2.3. Correlation between behavioral deficits and dopaminergic (TH+) neuronal loss in the SNpc
induced by successive PGJ2 microinfusions. (A) All groups of rats treated with PGJ2 (shades of red
circles) exhibited behavioral deficits. When compared to DMSO-treated rats (white, gray and black
circles), those treated with 2X and 4X PGJ2 significantly increased usage of the ipsilateral forelimb
as assessed by the cylinder test (see Materials and Methods). Statistical significance was estimated
with the Student's T-test to compare DMSO and PGJ2-treated groups and between two PGJ2treated groups. The p values in red indicate the values that are significantly (<0.05) different from
DMSO-injected rats. N =4 to 5 rats per group. (B) In the PGJ2-treated but not in the control (DMSO)
rats, dopaminergic neuronal loss (TH+) in the ipsilateral SNpc (x-axis) inversely correlates with
forelimb usage asymmetry (y-axis).
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2.4.3. PGJ2-treatment alters the morphological/functional properties of activated microglia
in the rat SNpc, but does not change microglia total numbers in the same area
We analyzed the number of microglia in DMSO and PGJ2-treated rats. The intact
contralateral SN served as the control for each rat. We thus evaluated and compared the activated
microglia numbers for each rat, as a ratio between ipsilateral over contralateral sides.
Due to the surgical procedure, SN injections of DMSO alone increased microglia activity
as assessed by Iba1 immunostaining. Compared to DMSO-treatment, PGJ2 did not significantly
(p>0.07) change the overall numbers of activated microglia, (Fig. 2.4A and B).
Activated microglia exhibit a remarkable variety of morphologies that can be associated
with their particular functions

187

. Using binary images of individual microglia silhouettes, we

distributed activated microglia into three different groups according to their form factor (FF)
value (Fig. 2.4C), which is defined as 4π X area / perimeter2
groups is defined as follows

188

. Each of the three microglia

187

: Ramified, FF: 0 to 0.5; actively engaged in neuronal

maintenance providing neurotrophic factors. Reactive, FF: > 0.5 to 0.7; responsive to CNS injury.
Amoeboid, FF > 0.7 to 1; cell body is amorphous with pseudopodia.
Based on the FF values, we observed a significant rise in reactive (p=0.026) and
amoeboid (p=0.005) microglia in PGJ2-treated rats compared to the DMSO-treated ones (Fig.
2.4D). The rise in reactive and amoeboid microglia was only detected in rats treated with two
PGJ2 injections and sacrificed four weeks post-injection (Fig. 2.4D). The microglia rise was not
apparent in the PGJ2-treated rats eight weeks post-injection. The plotted values represent the
ratio between ipsilateral over contralateral sides for each rat, normalized to the ramified
microglia, which are the ones associated with normal physiological function.
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Fig. 2.4. Successive PGJ2 microinfusions induce microglia morphological and functional changes
detected post-mortem. (A) TH (blue, dopaminergic) and Iba1 (red, microglia) immunostaining shows a
gradual loss of dopaminergic neurons and gain of activated microglia in the ipsilateral SNpc. Scale bar
= 50 µm. (B) The overall numbers of microglia in the ipsilateral SNpc did not significantly change
between DMSO (control) and PGJ2–treated rats. (C) Microglia morphologic changes represented by
2
the form factor (FF) calculated as 4π X area / perimeter . (D) The number of reactive and amoeboid
microglia significantly increased in the ipsilateral SNpc of rats receiving two (2X) PGJ2 injections at
four weeks but not at eight weeks post-injections, compared to controls (DMSO-treated). Values on
the y-axis represent the ratios between the ipsilateral SNpc over the contralateral, normalized to the
number of ramified microglia. Black circles, control, DMSO-treated rats; red circles, PGJ2-treated rats.
Statistical significance was estimated with the Student's T-test to compare DMSO and PGJ2-treated
groups and between two PGJ2-treated groups. The p values in red indicate significant (p<0.05)
difference from DMSO-injected rats. N = 3 rats per group.
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2.4.4. PGJ2-treatment increases the astrocyte reactivity in the rat SNpc
Astrocytes in the brain become reactive under pathological conditions, including in
neurodegenerative diseases

189

. Under these conditions, reactive astrocytes overexpress GFAP,

and undergo morphological changes (hypertrophy and process remodeling) 189.
Our studies demonstrate that, compared to DMSO, rats that received two PGJ2
microinjections exhibited, in the SNpc, a significant (p=0.049) increase in the reactive astrocytes
eight weeks, post-injections (Fig. 2.5A and B). The reactive astrocytes in the other groups of
PGJ2-treated rats (2X, 4wks, p=0.152; 4X, 4wks, p=0.179) was non-significantly different from
controls.
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Fig. 2.5. Successive PGJ2 microinfusions induce sustained astrocyte reactivity. (A) TH (blue,
dopaminergic) and glial fibrillary acidic protein (GFAP, green, reactive astrocytes) immunostaining
shows a gradual loss of dopaminergic neurons concurring with astrocyte reactivity in the ipsilateral
SNpc. Scale bar = 50 µm. (B) PGJ2-treated rats show significantly increased astrocyte reactivity in the
ipsilateral side of the SNpc compared to controls (DMSO-treated) at eight weeks after two (2X)
injections. Values on the y-axis represent the ratios between the ipsilateral SNpc over the
contralateral. Black circles, control, DMSO-treated rats; red circles, PGJ2-treated rats. Statistical
significance was estimated with the Student's T-test to compare DMSO and PGJ2-treated groups and
between two PGJ2-treated groups. The p value in red indicates significant (p<0.05) difference from
DMSO-injected rats. N = 3 rats per group.
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2.4.5. Detection of intraneuronal aggregate-like inclusions of ubiquitinated proteins and
phosphorylated (pS129) α-synuclein in SNpc DA neurons of rats treated with PGJ2
The accumulation of proteinaceous intraneuronal inclusions known as Lewy bodies in
SNpc DA neurons is one of the hallmarks of PD
proteins

191

190

. These inclusions contain ubiquitinated

as well as α-synuclein phosphorylated at S129 (pS129 α-syn)

20

. We addressed this

aspect of PD (Fig. 2.6A for ubiquitinated proteins, and 6B for pS129 α-syn, both quantified in
6C) by focusing on the TH+ DA neurons of the SNpc. Since our preceding studies already
demonstrated the progressive nature of the PGJ2-induced rat model, for this analysis and all
subsequent studies we focused only on four experimental paradigms: rats treated with two
injections or four injections of DMSO or PGJ2, and sacrificed four weeks post-injections.
Regardless of the number of PGJ2 injections, there was a shift from a diffuse distribution
of ubiquitinated proteins and pS129 α-syn detected in TH+ neurons of DMSO-treated rats, to
more of an aggregated appearance observed in the PGJ2-treated rats (white arrows, Fig. 2.6A
and B). Moreover, we established that only treatment with four (not two) PGJ2 injections
induced a significant (p=0.016) rise in the levels of ubiquitinated proteins in the few spared TH+
neurons (Fig. 2.6C, left panel). The levels of pS129 α-syn also increased under these conditions,
almost reaching statistical significance (p=0.089, Fig. 2.6C, right panel).
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Fig. 2.6. Successive PGJ2 microinfusions induce aggregate-like ubiquitinated proteins (A) and pS129
α-synuclein deposits (B) in dopaminergic neurons. Immunostaining for ubiquitinated proteins (red in
A), pS129 α-synuclein (red in B), and TH+ neurons (blue in A and B) at four weeks after two (2X) and
four (4X) PGJ2 microinjections. Dopaminergic neurons in the SNpc of PGJ2-treated rats exhibit
aggregate-like ubiquitin conjugates and pS129 α-synuclein neuronal inclusions (white arrows). Scale
bar = 50 µm. (C) Values on the y-axis represent the optical density (OD) ratios between ipsilateral
SNpc over the contralateral, normalized to the TH+ signal. Black circles, control, DMSO-treated rats;
red circles, PGJ2-treated rats. Statistical significance was estimated with the Student's T-test to
compare DMSO and PGJ2-treated groups. The p value in red indicates significant (p<0.05) difference
from DMSO-injected rats. N = 3 rats per group.
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2.4.6. Cell-type distribution and levels of key factors of the prostaglandin D2/J2 pathway
Up to now our findings corroborated that PGJ2-treated rats develop PD-like pathology in
a progressive temporal manner. We wanted to take our in vivo investigation one step forward and
address the impact of PGJ2 on the cell-type distribution and levels of key factors of the
prostaglandin D2/J2 pathway observed during the four-week window, including COX-2, the
PGD synthase L-PGDS, the PGD2/J2 receptor DP2, and the prostaglandin dehydrogenase 15PGDH (Fig. 2.7). We would like to highlight that the cell-type distribution and levels of these
four factors has never been investigated under control or stress conditions in the SNpc in relation
to PD, at least to our knowledge. Like for the ubiquitinated proteins and α-syn studies, we
focused only on four experimental groups: rats treated with two injections or four injections of
DMSO or PGJ2, and sacrificed four weeks post-injections.
We examined by immunocytochemistry, the distribution and levels of these factors in DA
neurons and microglia in the SNpc by assessing the optical density ratio or co-localization of
each of these factors with TH or Iba1, respectively. There was no significant difference in the
levels of these four factors in DA neurons (Fig. 2.7A to D, left) in rats that received 2X PGJ2
injections (red circles) compared to controls (DMSO-treated, black circles). In contrast, COX-2,
L-PGDS, and 15-PGDH levels increased significantly in the DA neurons of PGJ2-treated rats
that received four injections, when compared to controls (Fig. 2.7A, B and D, left). The DP2
receptor levels were stable in control and PGJ2-treated (4X) rats (Fig. 2.7C).
In regard to microglia, there was more variation in their responses to PGJ2-treatment.
Starting with COX-2, we observed a rise in its levels in rats treated twice with PGJ2, but not in
those treated four times with PGJ2, compared to controls (Fig. 2.7A, right). For L-PGDS,
significant increases were detected in both groups of PGJ2-treated rats compared to controls (Fig.
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2.7B, right).
Notably, DP2 receptors in microglia were almost non-existent or expressed at very low
levels (Fig. 2.7C, right, and Table 1). When considering ipsilateral and contralateral SNpc
separately, values representing the number of microglia exhibiting co-localization of the other
three factors (COX-2, L-PGDS, 15-PGDH) with the microglia marker Iba1, varied between 250
and 117 (not shown). However, for the DP2 receptor, these values ranged from 50 to 17 (Fig. 2.7,
Table 1), thus they were 2 to 15 times lower. We suspect that co-localization of DP2/Iba1
immunostaining is a paradox, and is most likely due to the proximity of a microglia to a DA
neuron.
The microglia levels of the prostaglandin dehydrogenase 15-PGDH did not change in any
of the control or PGJ2-treated groups of rats (Fig. 2.7D, right). We found that this enzyme was
expressed in another cell type, i.e. oligodendrocytes. The latter were detected in the SNpc of all
groups of rats with the marker for mature oligodendrocytes, the pi form of glutathione-Stransferase (GST-Pi, Fig. 2.7E).
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Fig. 2.7. PGJ2 microinfusions increase COX-2 (A) and L-PGDS (B) levels in dopaminergic neurons
and microglia. Immunostaining for COX-2 (red in A), L-PGDS (red in B), TH+ neurons (blue in A, B)
and Iba1+ microglia (green in A, B) at four weeks after two (2X) and four (4X) PGJ2 microinjections.
Scale bar = 50 µm. (A) COX-2 is significantly increased in dopaminergic neurons from rats receiving
four (4X) PGJ2 injections than in controls. Co-localization of COX-2 and Iba1 is greater in microglia
from rats receiving two (2X) PGJ2 injections than in controls. (B) L-PGDS is significantly increased in
dopaminergic neurons from rats receiving four (4X) PGJ2 injections than in controls. Co-localization of
L-PGDS and Iba1 is greater in microglia from rats receiving two (2X) and four (4X) PGJ2 injections
than in controls. Values on the y-axis represent the optical density (OD, normalized to TH, left graphs
in A and B) or co-localization (normalized to Iba1, right graphs in A and B) ratios between ipsilateral
SNpc over the contralateral. Black circles, control, DMSO-treated rats; red circles, PGJ2-treated rats.
Statistical significance was estimated with the Student's T-test to compare DMSO and PGJ2-treated
groups. The p value in red indicates significant (p<0.05) difference from DMSO-injected rats. N = 3
rats per group.
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2X, 4 weeks

4X, 4 weeks

# of Co - Lo
DP2 & Iba1
(SNpc)

Control

PGJ2

Control

PGJ2

Contralateral

29.7 ± 2.9

21.7 ± 2.3

17.3 ± 4.7

30.7 ± 2.7

Ipsilateral

24.3 ± 6.0

20.7 ± 0.3

22.3 ±1.5

50.7 ± 3.9

Fig. 2.7. (cont.) DP2 receptors (C) are predominantly expressed in the SNpc dopaminergic neurons
and not in microglia. Immunostaining for DP2 (red), TH neurons (blue) and Iba1 microglia (green) at
four weeks after two (2X) and four (4X) PGJ2 microinjections. Scale bar = 50 µm. (C) DP2 levels
remain stable in dopaminergic neurons from all treatment groups. Values on the y-axis represent the
optical density (OD, normalized to TH, left graph in C) or co-localization (normalized to Iba1, right
graph in C) ratios between ipsilateral SNpc over the contralateral. Black circles, control, DMSOtreated rats; red circles, PGJ2-treated rats. Statistical significance was estimated with the Student's Ttest to compare DMSO and PGJ2-treated groups. The p value in red indicates significant (p<0.05)
difference from DMSO-injected rats. Table 2.1 - Low detection levels of DP2 and Iba1 co-localization
in microglia. N = 3 rats per group.
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Fig. 2.7. (cont.) 15-PGDH (D, E) is detected in dopaminergic neurons, microglia and
oligodendrocytes in the SNpc. Immunostaining for 15-PGDH (red), TH neurons (D, blue), Iba1
microglia (D, green), and GST-pi oligodendrocytes (E, green) at four weeks after two (2X) and four
(4X) PGJ2 microinjections. Scale bar = 50 µm. (D) 15-PGDH expression is increased in dopaminergic
neurons from rats receiving four (4X) PGJ2 injections, but not in microglia. Values on the y-axis
represent the optical density (OD, normalized to TH, left graph in D) or co-localization (normalized to
Iba1, right graph in D) ratios between ipsilateral SNpc over the contralateral. Black circles, control,
DMSO-treated rats; red circles, PGJ2-treated rats. Statistical significance was estimated with the
Student's T-test to compare DMSO and PGJ2-treated groups. The p value in red indicates significant
(p<0.05) difference from DMSO-injected rats. N = 3 rats per group. (E) 15-PGDH is highly expressed
in SNpc oligodendrocytes from all groups of rats.
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2.4.7. Ibuprofen prevents most of the PD-like pathology developed in PGJ2-treated rats
Ibuprofen (IBP) is an NSAID that inhibits COX-1 and COX-2, thus reducing the
synthesis of all prostaglandins

150;154

up-regulation in neuronal cells

138

. We previously demonstrated that PGJ2 induces COX-2

, potentially establishing a positive feedback loop between

PGJ2 and COX-2. This positive feedback effect of PGJ2 on COX-2 could promote the transition
from acute to chronic neuroinflammation and consequently promote progressive PD pathology.
To determine the contribution of the cyclooxygenase pathway to the PGJ2-induced PDlike pathology in vivo, we administered IBP to the PGJ2-treated rats. The four groups of rats (2X
DMSO ± IBP and 2X PGJ2 ± IBP) were analyzed at four weeks post the last PGJ2 treatment,
with the cylinder test and immunochemistry. Preventive cyclooxygenase inhibition with IBP
starting the day after the first surgery, ameliorated all PD-like pathology induced by PGJ2,
except for reactive astrocytes (Fig. 2.8).
It is clear that IBP reduced DA neuronal loss (Fig. 2.8A and B), as well as reactive and
amoeboid microglia rise (Fig. 2.8A, C and D) in the SN, and prevented the bias toward use of the
ipsilateral over the contralateral forelimb (Fig. 2.8F). There was no statistical difference between
DMSO and PGJ2-treated rats that were fed IBP in relation to these four parameters: numbers of
TH+ cells (Fig. 2.8B), reactive (Fig. 2.8C) and amoeboid (Fig. 2.8D) microglia, and bias toward
use of the ipsilateral over the contralateral forelimb (Fig. 2.8F). These results support the
preventive effects of IBP in terms of PD-like pathology induced by PGJ2, a mediator of
inflammation.
In contrast, IBP administration significantly (p=0.05) increased the astrocyte reactivity
upon PGJ2-treatment, compared to DMSO-treatment (Fig. 2.8A and E). Thus, we show that
PGJ2-treatment causes sustained astrogliosis, which is not alleviated by the IBP treatment (Fig.
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2.5 and 2.8A and E). We should note that the role of astrocytes in PD pathology is ambiguous as
activated astrocytes can produce both pro-inflammatory and anti-inflammatory factors, as well as
neurotoxic and neurotrophic factors 26. The types of reactive astrocytes that are induced by PGJ2
± IBP remain to be investigated.
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Fig. 2.8. Ibuprofen ameliorates the PD-like pathology induced by PGJ2 except for astrocyte activation.
(A) Ibuprofen treatment starting the day after the first surgery reduces TH+ (blue, dopaminergic)
neuronal loss and Iba1+ (red, microglia) activation, but not GFAP+ (green, astrocyte) reactivity in the
SNpc at four weeks (4w) post two (2X) PGJ2-injections. Scale bar = 500 µm. (B) There was no
statistical difference in TH+ DA neurons between ibuprofen-fed PGJ2-treated rats and ibuprofen-fed
controls (DMSO-treated). The extent of PGJ2 damage was assessed by calculating the total number
of TH + neurons (mean ±SEM) in the SNpc using unbiased stereology as described in Materials and
Methods. (C, D) There was no statistical difference between the number of reactive (C) or amoeboid
(D) microglia in ibuprofen-fed PGJ2-treated rats and ibuprofen-fed controls (DMSO-treated). (E)
Astrocyte reactivity is significantly higher in ibuprofen-fed PGJ2-treated rats than in ibuprofen-fed
controls (DMSO-treated). For A through E, N=3 rats per group. Values on the y-axis represent the
ratios between the ipsilateral SNpc over the contralateral (in C and D normalized to the number of
ramified microglia). (F) There was no statistical difference in motor asymmetry between ibuprofen-fed
PGJ2-treated rats and ibuprofen-fed controls (DMSO-treated). For F, N = 5-7 rats per group. Black
circles, control, DMSO-treated rats; red circles, PGJ2-treated rats. Statistical significance was
estimated with the Student's T-test to compare DMSO and PGJ2-treated groups. The p values in red
indicate significant (p<0.05) difference from DMSO-injected rats.
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2.5. DISCUSSION
The frequent failure of potential new treatments in clinical trials suggests that current PD
models that are used to test them, may not exhibit the critical and/or complete set of PD traits
experienced in humans. Other types of animal models relevant to PD need to be developed.
Compelling evidence supports that neuroinflammation, and in particular the cyclooxygenase
pathway, plays a central role in PD 149-154. However, very few studies address how prostaglandin
products of cyclooxygenases redirect cellular events to promote neurodegeneration in PD. In the
current studies, we developed a non-transgenic rat model of neuroinflammation by microinfusing
PGJ2 unilaterally into the right SNpc. The PGJ2-treated rats displayed DA neuronal loss that
correlates with motor deficits, as well as gliosis including increases in activated microglia and
reactive astrocytes. The DA neurons in the SNpc developed aggregate-like ubiquitinated proteins
and pS129 phosphorylated α-synuclein deposits. We showed that PGJ2 induces the accumulation
and aggregation of ubiquitinated proteins in rat cortical neurons

192

. All of these traits are

characteristic of human PD-pathology.
This new PGJ2-induced rat model offers several advantages over other PD models. In the
first place, we identified elements of the prostaglandin D2/J2 pathway that may be effective
novel therapeutic targets for PD, downstream of the cyclooxygenase pathway. Based on our data,
we propose that DP2 receptor antagonists and L-PGDS inhibitors could be new drugs that
prevent/diminish PD pathology associated with neuroinflammation. DP2 receptors bind PGD2
and PGJ2 with similar affinities (nanomolar range) 111;193. DP2 receptors are Gi-protein-coupledreceptors, and their activation downregulates cAMP and increases intracellular calcium levels
117;194

. We found that DP2 receptors in rats are abundantly expressed in DA neurons of the SNpc,

while almost lacking in microglia. Thus, PGD2/J2 produced by activated microglia could lead to
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aggravated DA neuronal damage via DP2 receptor activation. On the other hand, DP2 inhibition
could ameliorate neuronal dysfunction. In support of neuroprotection accomplished by blocking
DP2 receptors, DP2 antagonists [CAY10471 and its BAY-u3405 (ramatroban) analog] were
found to attenuate pain in a peripheral nerve injury rat model

195

. In addition, CAY10471 was

shown to increase survival of rat hippocampal neurons exposed to aluminum 196. In contrast, DP2
activation was shown to potentiate neuronal injury in rat hippocampal neuronal cultures and
organotypic slices

101;112

. Based on all of these findings, we propose that DP2 antagonists will

protect DA neurons from the neurotoxic effects of activated microglia in PD, in particular SNpc
DA neurons, which exhibit low calcium buffering capacity 6.
In regard to L-PGDS, this enzyme is responsible for most PGD2 synthesis in the brain,
and is one of the most abundant cerebrospinal fluid (CSF) proteins 103, representing ~3% of total
CSF proteins

197

. We established that PGJ2-treated rats display increased L-PGDS levels,

suggesting that L-PGDS inhibitors may protect neurons from PGD2/J2-induced PD-pathology.
The following studies support this premise. Cortical neurons derived from L-PGDS null mice
exhibited higher cell viability and less accumulation of ubiquitinated proteins in response to
hypoxic conditions, than those derived from L-PGDS heterozygous mice
identified as the major apoptotic factor in plasma of AD patients

109

113

. L-PGDS was also

. In addition, in vivo and in

vitro studies demonstrated that L-PGDS promotes reactive gliosis related to brain pathology
108;198

. Alterations in L-PGDS levels in the CSF, were detected in at least 20 idiopathic PD

patients compared to 100 controls

199

. These L-PGDS changes could indicate pathology at the

cellular level with an impact on PGD2/J2 levels, and also correlate with disease symptoms

199

.

Notably, the L-PGDS specific PET tracer that is a glutathione conjugate of fluorine-18-labeled
fluorobutyl ethacrynic amide ([18F]FBuEA-GS), is used to assess L-PGDS overexpression in
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brain tumors

200

. Potentially this radiotracer could be useful for PD diagnosis, by providing

information on changes in L-PGDS levels. Based on all of these studies, we propose that LPGDS could be considered a PD biomarker with predictive value 199, and could also be explored
as a potential drug target for therapeutic intervention in neuroinflammation-driven PD.
Prostaglandins are unstable, thus act as autocrine or paracrine ligands by exerting their
effects near their sites of synthesis

201

. The enzyme 15-PGDH inactivates prostaglandins in the

cytoplasm. Therefore, cyclooxygenases and 15-PGDH control prostaglandin cellular levels by
opposite means. Although 15-PGDH metabolizes neuroprotective as well as neurotoxic
prostaglandins, higher 15-PGDH levels may be beneficial under conditions where the effects of
neurotoxic prostaglandins outweigh those of the neuroprotective ones

119

. We found that in

PGJ2-treated rats the levels of 15-PGDH expression in DA neurons seemed equivalent to those
in control rats. In addition, we detected 15-PGDH in SNpc oligodendrocytes identified with
GST-Pi, the pi form of glutathione-S-transferase. The presence of 15-PGDH in oligodendrocytes
may represent a protective mechanism to counteract the increased oligodendrocyte vulnerability
to excitotoxic death associated with COX-2 up-regulation following, for example, glutamate
receptor activation 202.
The second advantage offered by the PGJ2-induced rat model is related to animal models
that recapitulate the disease phenotype with some degree of fidelity. These animal models should
be valuable for developing and testing new or repurposed therapeutic agents as well as magnetic
resonance imaging (MRI) and PET imaging tracers

203

. Our current studies show that when

administered prior to symptom development, ibuprofen, which inhibits COX-1 and COX-2,
prevented most of the PGJ2-induced PD-like pathology. This finding is important because it
demonstrates that PGJ2-induced neurodegeneration is mediated in part by activation of the
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cyclooxygenase pathway that could lead to chronic inflammation. In addition, our data support
that NSAIDs can be instrumental in preventing DA neurodegeneration associated with
inflammation. The conflicting epidemiological and clinical results on the potential use of
NSAIDs to treat PD, could be due to variations in (a) length of treatment (longer in
epidemiological and shorter in clinical studies), and/or (b) disease stage at the start of treatment
(pre-pathology in epidemiological and post-pathology in clinical studies), reviewed in

204

. The

PGJ2-induced rat model was also used to test a variety of PET tracers with the major intention of
assessing in vivo the progression and spreading of neuroinflammation, (manuscript in
preparation). These latter studies could help establish the optimal timeline for therapeutic
intervention, to prevent PD pathology linked to neuroinflammation.
Thirdly, we show that the PGJ2-induced PD-like pathology in the rats developed in a
progressive temporal manner, as it worsened with time up to 8 weeks post the second PGJ2
injection, the latest time-point that we analyzed. In animal models, the progressive nature of PD
neurodegeneration is a hard-to-mimic aspect of this disorder. Toxin and pharmacological
induced PD models such as 6-OHDA, MPTP, paraquat and rotenone exhibit motor symptoms,
but they are often related to massive and rapid degeneration of the nigrostriatal pathway

53

.A

similar phenomenon is observed in LPS-mediated models of PD, used to address the link
between neuroinflammation and PD pathology. LPS administered intracranially into the SN,
striatum or globus pallidus, causes DA neuronal loss within 24 hours that persists at the same
level by 30 days, therefore not mimicking the progressive nature of PD pathology

72;74

. Single

systemic administration of LPS causes progressive dopaminergic neuronal loss, although
microglia activation is not specific to the SN, being detected in a variety of brain regions 71.
Fourthly, we established that PGJ2 has similar neurotoxic effects in rats and mice, as we
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previously described for the PGJ2-induced mouse model that displayed comparable PD-like
pathology

86;87

. This is not the case for all drug based PD models, some of which are species-

specific. For example, rats are resistant to MPTP and the MPTP-sensitivity differs widely among
various strains of mice 52. Moreover, not all PD animal models exhibit DA neuronal degeneration
and correlated motor deficits, as we detect in the PGJ2-induced rat model. For example, PD
models based on genetic risk factors such as Parkin, PINK1 and LRRK2 show little or no
nigrostriatal degeneration and motor symptoms

51

. Most PD models, transgenic and non-

transgenic, exhibit some level of neuroinflammation usually detectable early and sometimes even
pre-symptom development

15;75

. It is thus advantageous to address novel targets of

neuroinflammation, such as we do in the current study.
In conclusion, the PGJ2-induced rat model of neuroinflammation that we developed
provides an optimal tool to study the relationship between PGD2/J2-induced chronic
inflammation and progressive neurodegeneration relevant to PD, to test therapeutics, such as
DP2 antagonists and L-PGDS inhibitors to prevent/diminish DA neurodegeneration linked to
neuroinflammation and PD, and to evaluate novel PET tracers to determine the in vivo
progression of PD-like pathology and establish the optimal temporal window for therapeutic
intervention.
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CHAPTER III

µPET imaging of gliosis with [11C]PK11195 in a PGJ2-induced rat model of
neuroinflammation exhibiting progressive parkinsonian-like pathology

Chuhyon Corwin

Department of Biology,
Hunter College of the City University of New York,
New York, New York 10065

57

3.1. ABSTRACT
Upregulation of COX-2 plays a key role in neuroinflammation associated with PD. In
addition, epidemiological studies indicate that the use of COX inhibiting NSAIDs lowers the risk
for developing PD. However, NSAIDs are not used as a treatment against PD due to their serious
side effects. Investigations into the role of prostaglandins and other downstream factors of the
COX pathway is desirable in order to explore anti-inflammatory treatment options against
neurodegenerative diseases.
PGD2, the most abundant prostaglandin in the brain, is upregulated upon brain injuries
and is converted to the highly neurotoxic PGJ2 by spontaneous dehydration. Chapter 2 discussed
our newly developed rat model of neuroinflammation induced by PGJ2 that models, in part, the
progressive nature of PD pathology. DMSO (vehicle) or PGJ2 were microinfused into the right
side of the SN of adult Sprague Dawley male rats for two weeks (once per week). PGJ2-treated
rats exhibited motor deficits correlated with progressive dopaminergic neuronal loss.
Immunohistochemical analyses confirmed the increased activation of microglia and chronically
reactive astrocytes in the PGJ2-treated rats.
We assessed in vivo chronic neuroinflammation in the PGJ2-induced rat model. We
compared µPET imaging with the translocator protein (TSPO) radioligand [11C]PK11195, at
week four and eight post DMSO and PGJ2-injections. Rats that received two PGJ2-injections
showed higher [11C]PK11195 uptake compared to controls (DMSO-treated) at both time points,
demonstrating chronic glial activation in the PGJ2-injected side of the SN.
In conclusion, chronic neuroinflammation present in the PGJ2-induced rat model of PD
can be monitored and assessed in vivo by PET imaging. The PGJ2 rat model may help identify
and optimize treatments against neurotoxic inflammation to prevent/slow the development and
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progression of PD. In addition, this novel rat model can aid in the evaluation of novel PET
radiotracers for neuroinflammation.
3.2. INTRODUCTION
Chronic neuroinflammation is associated with neurodegenerative diseases such as PD
26;149-151;154;205

. However, the mechanisms by which neuroinflammation contributes to the onset

and progression of PD remain unclear.
The COX pathway plays an important role in neuroinflammation. The activity of the
COX pathway increases with normal aging

78

and contributes to neurodegeneration through

overexpression of COX-2 in the SNpc of PD brains 48. Epidemiological studies strongly support
the beneficial effect of NSAIDs in lowering the risk for developing PD

5;22;49

. Nevertheless,

NSAIDs are not widely recommended as a treatment for PD because they have many toxic
effects

140;206

. Besides NSAIDs there is no approved clinical drug that can slow or stop

neurodegeneration in PD.
One of the major challenges in the development of therapeutics for PD is the lack of
biomarkers. Validated biomarkers would confirm the diagnosis, objectively determine pathology
stages, and improve treatment efficacy by optimizing the temporal window for intervention.
Biomarkers that indicate early phases of pathology are desired because early intervention may
increase the chance for therapeutic success by preventing or halting neurodegeneration.
PET imaging has been successfully employed for the last three decades in the assessment
of neurological diseases, such as PD (reviewed in

207

). Radiotracers designed for specific targets

allow the characterization of different disease processes. Measurement of the in vivo distribution
of these targets can reveal valuable information about their physiology and role in the disease
state. Animal studies can take advantage of µPET as currently available µPET imaging systems
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provide rat brain images of high resolution

144;145

, while immunohistochemical analyses can

confirm µPET findings by providing data at the cellular level 146.
We established a rat model of neuroinflammation induced by PGJ2 that mimics
hallmarks of PD pathology including activation of microglia and astrocytes commonly detected
in the SN of PD brains

36;37;39

. Immunohistochemistry analyses (Chapter 2, Fig. 2.4 and 2.5)

showed that the PGJ2-treated rat brains exhibit activation of microglia and astrocytes at week
four and eight post-injection, along with progressive neurodegeneration, a challenging aspect to
model for PD. Therefore, the PGJ2 rat model of PD-like pathology can be used for longitudinal
µPET studies and help identify biomarkers that may vary depending on the degree of the
pathology. In collaboration with Weill Cornell Medicine (Dr. Anastasia Nikolopoulou, Dr.
Yeona Kang, and Dr. John Babich), we visualized microglia and astrocyte activation in the
PGJ2-treated rat brains. We used [11C]PK11195, a PET radiotracer that has been widely
validated in clinical research for studying CNS disorders, including PD 208;209.
3.3. MATERIALS AND METHODS
3.3.1. Materials - The PGJ2 (cat. # 18500, Cayman Chemical) dosage used in the study was 33.4
µg in 2 µL solution. The final DMSO concentration in PBS was 17% for all microinfusions. The
solutions were freshly prepared and stored at 4°C and in the dark.
3.3.2. Rats - All procedures were performed in accordance with the NIH Guidelines for the Care
and Use of Laboratory Animals and were approved by the Institutional Animal Care and Use
Committees at Weill Cornell Medicine. Young adult Sprague Dawley male rats from Envigo
(Frederick, MD) were used at 18 weeks of age at the time of the first injection. Rats were
acclimated for one week before the surgery and had food and water available ad libitum on a 12-
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hour light/dark cycle.
3.3.3. Stereotaxic surgery – Surgical procedures were followed as described in Chapter 2. All
rats received unilateral microinfusions into the right side of the SN. No injections were given on
the left side of the SN, which served as the internal control. Each rat received one injection per
week for two weeks with DMSO or PGJ2 (33.4 µg in 2 µL DMSO).
3.3.4. Groups - Rats were randomly assigned to the treatment groups (2X DMSO, N=4 or 2X
PGJ2, N=3).
3.3.5. µPET imaging – [11C]PK11195-PET was performed at week four and eight after the last
intranigral injection [DMSO (vehicle) or PGJ2] using the Inveon® imaging system (Siemens
Medical Solutions USA, Inc.). Each rat was first inserted with an i.v. catheter in the tail vein
after induction of anesthesia (isoflurane at 3-4% in medical air for induction, and 2% for
maintenance), and then placed in the transaxial position with its head in the center of the scanner
field of view. The radiotracer (Dose: 1.0-1.5 mCi / 0.3-0.5 mL) was injected as a bolus over 20
sec and a 60 min dynamic scan starts with 24 time frames. The emission data was reconstructed
with OSEM2D (2 iterations, 16 subsets) with final images having a voxel size of 0.78×0.78×0.80
mm. The T1-weighted MRI brain reference template was generated from normal rats using a 7T
animal MRI scanner. The MRI template was co-registered to the corresponding µPET images
and Region of Interests (ROIs) were manually drawn around SN onto the MRI template using
the Paxinos and Watson 7th edition Rat Brain Atlas for guidance. For kinetic analysis, the Logan
method was used and quantitative data was expressed as ratio of the volumes of distribution (VT)
between the ipsilateral and the contralateral sides (ipsi/contra).
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Adult Male Sprague-Dawley Rats
(18 weeks of age at the time of 1st injection)
PGJ2 [33.4 µg in (DMSO/PBS, 17 %)] or
control (DMSO/PBS, 17 %)
Unilateral injections (2 µL) into right SNpc
2X Injections:
PGJ2 or
DMSO (Control)

+ 4 weeks
µPET - [11C]PK11195

+ 4 weeks
µPET - [11C]PK11195
Fig. 3.1. Schematic representation of the experimental design for µPET imaging. Eighteen-week-old
male Sprague Dawley rats were microinjected twice into the right substantia nigra pars compacta
(SNpc) with DMSO (control; 17% in PBS) or PGJ2 (33.4 µg) in 2 µL DMSO/PBS, at weekly intervals.
Each rat was imaged at week four and eight after the last microinjection. 2X DMSO, N=4 or 2X PGJ2,
N=3.
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3.4. RESULTS
3.4.1. PGJ2 induces chronic neuroinflammation that can be monitored in vivo with µPET
imaging – DMSO and PGJ2-treated rats were imaged at week four and again at week eight after
the last intranigral injection (Fig. 3.1). µPET images (Fig. 3.2) show the uptake and distribution
of [11C]PK11195 in the rat brains. At week four post-injections, high radioactivity localization is
observed in the injected side of the SN of treated rats. Radioactivity uptake is significantly higher
in PGJ2-treated rats compared to controls. At week eight post-injection, [11C]PK11195 uptake in
the SN of PGJ2-treated brains is reduced compared to week four, but it is still significantly
higher than control brains. Quantitative imaging data are summarized in Table 3.1.
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[11C] PK11195
scans

2X, 4wks
(mean±SD)

2X, 8wks
(mean±SD)

p-value (B)

(%) Change

Control (N=4)

1.23±0.16

1.03±0.11

0.03

21.76% ↓

PGJ2 (N=3)

1.55±0.1

1.37±0.15

0.02

15.69% ↓

p-value (A)

0.01

0.02

Fig. 3.2. Glial activation induced by successive PGJ2 microinfusions is detected in vivo using
11
[ C]PK11195. µPET images were taken from rats injected with DMSO or PGJ2. White arrows
indicate the microinfusion sites. Coronal representative µPET images are shown. Increase in
11
[ C]PK11195 binding was detected in PGJ2-treated compared to DMSO-treated rats. L and R, rat left
and right sides, respectively. Table 3.1 - Volume Distribution (VT) ratios (ipsilateral / contralateral
11

11

sides) for [ C]PK11195. PGJ2-treated rats exhibited significantly higher uptake of [ C]PK11195 in
the injected (ipsilateral) side of the SN at both times compared to the control rats [p-value (A)].
11
[ C]PK11195 uptake is reduced at eight weeks compared to four weeks in both PGJ2 and control
groups, but less in the PGJ2 group [p-value (B)]. N = 3-4 rats per group. The p values were
established with the Student's T-test. The p values in red indicate significant (p<0.05) difference.
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3.5. DISCUSSION
In order to validate the use of µPET to image gliosis in the PGJ2-treated rat model, we
used the radiotracer [11C]PK11195, which is a TSPO selective ligand. TSPO is one of the
subunits of the mitochondrial permeability transition pore, and is found in many tissue types in
the periphery as well as in the brain 208. Normally, TSPO levels are very low in the brain, but its
mitochondrial expression increases in activated microglia and astrocytes upon brain injury or
insult 210;211. Therefore, TSPO serves as a marker for detection of glial activation 212.
PD brains exhibit increased activation of microglia and astrocytes

26;27;29

. During

neuroinflammation, prolonged activation of microglia and astrocytes results in the release of
various inflammatory mediators that further drive disease progression

30;31

. µPET data acquired

during these studies show that repeated PGJ2 injections induce chronic gliosis in the SN and is in
agreement with the immunohistochemical results described in Chapter 2 (Fig. 2.4 and 2.5).
Overall, our PET studies suggest that the PGJ2-induced rat model can be used to assess
the progression of neuroinflammation via PET imaging. Novel radioligands specific for
downstream factors of the COX pathway as identified in the studies discussed in Chapter 2, will
help identify biomarkers for PD during disease progression, and identify the optimal window for
therapeutic intervention.
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Approximately 750,000 to one million people in the U.S. suffer from PD and there is no
cure. The annual economic burden of PD is $19.8 to $26.4 billion and it is expected to rise with
the growth of the aging population: the U.S. population over 50 years of age is estimated to
increase by 46.2% over 30 years by the year 2040 213;214.
Since James Parkinson’s seminal paper 200 years ago on the first description of PD, our
knowledge in many aspects of PD have greatly increased from clinical description and
neuroanatomical pathology to physiological, cellular and molecular characteristics (reviewed in
215

), for which animal models have been instrumental. However, efforts to develop an animal

model that reproduces all aspects of PD pathology still face many obstacles mainly because the
exact causes of PD are unclear. Nevertheless, under the overarching multifactorial hypothesis of
PD etiology, neuroinflammation is known to be crucial to PD neuropathology. Chronic
neuroinflammation in particular promotes the progression of PD.
COX-2, found to be highly expressed in PD brains
positive feedback loop

138;139

48

, is up-regulated by PGJ2 via a

. Therefore, our studies aimed to establish a rat model of PD based

on chronic neuroinflammation induced by PGJ2, the most neurotoxic prostaglandin of the COX
pathway that we tested.
Our studies show that the PGJ2-induced rat model of PD exhibits: (a) a dose-dependent
and temporal progression of DA neuronal loss in the SNpc with non-significant effects on
neurons in nearby brain regions, such as the VTA and the SNpr; (b) a motor deficit correlation
with the loss of DA neurons in the SNpc; (c) microglia activation and sustained astrogliosis;
(d) neuroinflammation confirmed in vivo by µPET imaging using the radioligand [11C]PK11195
at four weeks and eight weeks post the last PGJ2-injection; and (e) increased accumulation of
ubiquitinated proteins and pS129 α-synuclein in potentially degenerating DA neurons.

67

A five-week-long ibuprofen treatment, initiated on the next day following the first PGJ2
injection, improved motor deficits and DA neuronal loss in the PGJ2-induced rat model of PD.
Ibuprofen effectively reduced microglia activation, but had no significant preventive effect on
astrogliosis. While epidemiological studies support the benefit of NSAID treatment in lowering
PD risk, our findings with the PGJ2-induced rat model support that ibuprofen prevents DA
neuronal loss. The protective effects of ibuprofen may depend on the dosage and timeline of
treatment.
Based on our studies, we hypothesized that DA neuronal loss triggered by PGJ2-induced
chronic neuroinflammation is driven by changes in the levels of COX pathway factors present in
DA neurons and microglia. Our data suggest the following mechanisms and potential therapeutic
approaches:
1) Targeting L-PGDS: Immunohistochemistry analyses showed that PGJ2-treated rats
exhibited increased levels of COX-2 and L-PGDS, the brain synthase for PGD2 (PGJ2
precursor), in microglia and DA neurons. This finding suggests that L-PGDS inhibitors that
decrease brain PGD2 levels, have potential to protect neurons independently from DP receptor
activation. This premise is supported by a study with cortical neurons cultured under hypoxic
conditions

113

. Accordingly, cortical neurons derived from L-PGDS null mice exhibited higher

cell viability and less accumulation of ubiquitinated proteins than those derived from L-PGDS
heterozygous mice. These hypoxia-driven effects were not prevented by the administration of
DP1 or DP2 receptor antagonists

113

. In addition, PGD2 synthesized by L-PGDS promotes cell

migration and induces gliosis-like morphological changes as shown in mouse primary microglia
and astrocyte cultures incubated with PGD2

108

. In the same study, similar glial activation was

observed when glial cultures were incubated with mouse recombinant L-PGDS, supporting that

68

L-PGDS affects glia as a secreted lipocalin-like ligand, independently of PGD2 108. Moreover, LPGDS injections into the striatum of mouse brains induced GFAP-positive astrocyte migration to
the site of injection 108. Based on these studies, it is possible that down-regulating L-PGDS levels
will lessen gliosis in the PGJ2-treated rats and reduce the neurotoxic consequences of PGJ2.
Notably, PGD2 toxicity is mediated by its metabolites of the J-series prostaglandins 113.
2) Targeting the DP1 receptor: PGD2 and PGJ2 both induce cAMP upregulation by
binding to the DP1 Gs-protein-coupled-receptor with comparable affinities 110;111. DP1 activation
is reportedly neuroprotective, as shown in cultures and organotypic slices of rat hippocampus
exposed to N-methyl-D-aspartic acid (NMDA) and glutamate-induced toxicity 101, in young and
old mice undergoing NMDA-induced acute excitotoxicity
217

216

, and in an ischemia mouse model

. However, the use of DP1 agonists as neuroprotective agents must be approached with caution.

Microglia and astrocytes also express DP1 receptors, thus DP1 agonists may amplify gliosis,
which is an important point to consider in the light of the findings with AD brains. DP1 is
significantly upregulated in AD brains and upregulated DP1 was localized in GFAP-positive
activated astrocytes and reactive microglia within senile plaques

218

. PGD2 enhances microglia

activation via DP1 receptors, and PGD2 was reportedly responsible for sustaining degeneration
of rat hippocampal neurons over 30 days after kainic acid (KA)-induced excitotoxicity 219. While
further research is necessary to differentiate the beneficial and harmful types of activated
astrocytes in relation to the DP1 pathway, neuronal damage mediated by activated microglia is
known to be associated with DP1 activation 220.
3) Targeting the DP2 receptor: Binding of PGD2 or PGJ2 to the DP2 Gi-proteincoupled-receptor downregulates cAMP, increases intracellular calcium levels, and induces
subsequent neurotoxicity

117

. PGJ2 has a much higher affinity for DP2 than for DP1, the latter

69

playing a role in neuroprotection as described above. We established with the PGJ2-induced rat
model that DP2 receptors are abundantly expressed in DA neurons in the SNpc, while almost
lacking in microglia. Therefore, PGD2 produced by microglia can negatively affect DA neurons
via the DP2 receptor. A similar microglia-neuron interaction via DP2 receptors in neurons was
reported in a peripheral nerve injury rat model, in which DP2 antagonists [CAY10471 (Cayman
Chemical, Ann Arbor, MI), and its BAY-u3405 (ramatroban) analog] attenuated the pain

195

. In

addition, CAY10471 was shown to increase survival of hippocampal neurons exposed to
aluminum

196

. Based on all of these findings, we predict that DP2 antagonists could potentially

protect DA neurons from the damaging effects of activated microglia in the PGJ2-induced rat
model.
4) Targeting 15-PGDH: The key prostaglandin-degrading enzyme (15-PGDH) may be a
potentially effective therapeutic target to counteract the neurotoxic effects of COX-2
overexpression in PD. This notion is supported by cancer studies suggesting that COX-2 and 15PGDH reciprocally regulate each other

221;222

, (reviewed in

223

). COX-inhibiting NSAIDs

reportedly increase 15-PGDH expression in cancer cells (reviewed in

122

). However, COX-2

inhibition by NSAIDs is not directly linked to15-PGDH up-regulation. Instead, NSAIDs appear
to inhibit the protease responsible for the turnover of 15-PGDH (reviewed in 122).
15-PGDH deactivates a wide variety of prostaglandins with different affinities

119

.

Therefore, the benefit of activating 15-PGDH to protect against neuroinflammation is more
likely undermined by its lack of prostaglandin specificity, and by its potential higher affinity for
neuroprotective prostaglandins than for PGD2 119.
Finally, we found in the PGJ2-induced rat model that 15-PGDH levels in DA neurons
remains relatively low compared to mature oligodendrocytes. High expression of 15-PGDH may

70

enable oligodendrocytes to be resilient to the neurotoxic effect of PGD2, and offset the
neurotoxic effect of PGJ2. However, DA neurons in the SNpc are unmyelinated or thinly
myelinated

6

, and the role of oligodendrocytes may be limited to rescuing degenerating DA

neurons in the SNpc via axon-myelin interactions 224;225.
In conclusion, our findings suggest that the damaging effects of PGJ2/D2 could
potentially be minimized by inhibiting L-PGDS and/or by blocking DP2 receptors. Overall, the
PGJ2-induced rat model of neuroinflammation that we developed provides an optimal tool to
study: (1) the relationship between PGJ2-induced chronic inflammation and neurodegeneration
relevant to PD; (2) the in vivo progression of PD-like pathology with novel PET tracers; and (3)
therapeutic strategies to ameliorate the susceptibility of DA neurons to neuroinflammation
relevant to PD.
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PD is characterized by progressive degeneration of the nigrostriatal pathway leading to
motor deficits. The pathological hallmarks of PD are Lewy bodies, which are neuronal protein
aggregates that contain, among other proteins, α-synuclein and ubiquitinated proteins. With the
progression of the disease, the scope of affliction extends beyond the DA neurons in the SN, as
heterogeneous non-motor deficits become also common (reviewed in 5 and 6).
Chronic

neuroinflammation

is

undoubtedly

involved

in

the

initiation

and

pathophysiology of PD, as supported by findings from GWAS 15;16, epidemiological 49 and postmortem tissue studies
PD

75;76

19;25-27;29;48

, as well as research with genetic and toxin-induced models of

. One of the most pertinent aspects of neuroinflammation related to PD is the COX
, and COX activity increases with aging

78

Moreover, higher expression of COX-2 was reported in the ventral midbrain of PD patients

48

pathway. Aging is a major risk factor for PD

226-229

and variants of the cox-2 gene were found to be associated with PD

.

,

79;80

. These cox-2 variants

include a C8473T single nucleotide polymorphism (SNP) in the 3’-UTR region, and a 1195G>A polymorphism in the promoter region

79;80

. Epidemiological studies established that

COX-inhibiting NSAIDs lower the risk and development of PD

49

, though there has been no

report on its successful replication in clinical settings. Challenges of replicating the
epidemiological findings in clinical studies could be due to the adverse side effects of NSAIDs,
insufficient period of use, and/or the older age of cohorts at the initial time of intervention
(reviewed in204).
To address whether a product of the cyclooxygenase pathway could by itself induce PDlike pathology, we established a rat model of neuroinflammation induced by PGJ2
microinjections into the SNpc. We used the PGJ2-induced rat model to:
(1) Establish an in vivo correlation between PGJ2 and PD-like pathology.

73

(2) Characterize, for the first time ever, the prostaglandin D2/J2 pathway in the SNpc,
including COX-2, the PGD2 synthase L-PGDS, the DP2 receptor to which PGJ2 binds with a
high affinity (nanomolar range)

117;118

, and the prostaglandin dehydrogenase 15-PGDH. We

investigated the impact of PGJ2-treatment on the distribution and levels of these elements of the
prostaglandin D2/J2 pathway, in two major cell types in the SNpc: DA neurons and microglia.
(3) Evaluate the potential of ibuprofen, a non-selective NSAID that inhibits both COX-1
and COX-2, to prevent the PGJ2-induced PD-like pathology, including loss of DA neurons,
motor deficits and gliosis (microglia and astrocytes).
(4) Validate the longitudinal use of µPET imaging to assess the development of
progressive gliosis in vivo.
The PGJ2 rat model exhibited some of the essential characteristics of PD, including
progressive DA neuronal loss in the SNpc with the concomitant motor deficits, microgliosis as
well as astrogliosis, and the accumulation of ubiquitinated protein and phospho (pS129) αsynuclein.
Our findings on the distribution and levels of elements of the prostaglandin D2/J2
pathway, suggest that antagonists for the PGJ2-binding DP2 receptor could be of therapeutic
interest. The higher expression level of DP2 receptors in DA neurons compared to microglia,
supports an enhanced neuronal vulnerability to PGD2/J2 mediated toxicity, as PGD2/J2 bind to
DP2 with high affinity (nanomolar range). However, DP1 agonists, suggested by others to be
neuroprotective, could be hazardous to neurons. Microglia and astrocytes also express DP1
receptors, thus increases in PGD2/J2 levels could induce gliosis, ending up being harmful to
neurons. Alternatively, down-regulating L-PGDS activity leading reduced PGD2/PGJ2 levels,
could diminish PGD2/PGJ2-associated neurotoxicity and gliosis.

74

We also established that ibuprofen diminishes the PD-like pathology induced by PGJ2,
such as loss of DA neurons, motor deficits and microgliosis. Ibuprofen inhibits COX-1 and
COX-2, and also binds and activates the peroxisome proliferator-activator receptor gamma
(PPARγ). Activation of PPARγ has anti-inflammatory properties
proteins such as neuronal pentraxins

231

230

, and modulates immune

. Which of these ibuprofen actions mediates its

preventive effects in the PGJ2-induced rat model, remains to be investigated.
NSAIDs, including ibuprofen, target cyclooxygenases as well as the prostaglandin
degrading enzyme 15-PGDH in an inversely related manner, as shown in cancer cells 121;122;222.
Increased expression of 15-PGDH induced by NSAIDs may offset the effects of neurotoxic
prostaglandins. Although 15-PGDH metabolizes neuroprotective as well as neurotoxic
prostaglandins, higher 15-PGDH levels may be beneficial under conditions where the effects of
neurotoxic prostaglandins outweigh those of the neuroprotective ones.
Finally, µPET imaging with the TSPO radiotracer [11C]PK11195 showed that the levels
of activated microglia and reactive astrocytes can be assessed in vivo in the PGJ2-induced rat
model of neuroinflammation. We observed at two different post-injection time points (weeks
four and eight), that PGJ2-treatment induced a significant unilateral progressive uptake of
[11C]PK11195 in the SN. These data support that PGJ2, by itself, induces a rise in activated
microglia and reactive astrocytes, which could be contributing to the progressive nature of PD.
Based on our findings we suggest the following research directions to further characterize
the PGJ2-induced rat model of neuroinflammation relevant to PD, to validate its usefulness to
investigate the progression of PD-like pathology in vivo, and to test novel PD therapeutic options:
1. Characterize the types of activated astrocytes during chronic neuroinflammation – The
PGJ2-induced rat model of neuroinflammation shows that PGJ2-treatment caused sustained
75

astrogliosis, which was not alleviated by the ibuprofen treatment. Post-mortem studies of PD
brains confirm that significantly increased numbers of activated astrocytes are detected in the SN
26;29

. The role of astrocytes in PD pathology is ambiguous as activated astrocytes can produce

both pro-inflammatory and anti-inflammatory factors, as well as neurotoxic and neurotrophic
factors (reviewed in

26

). Thus, reactive astrocytes may exhibit two functional states: toxic (A1

type) or trophic (A2 type). More research on this aspect of astrocyte function is required, but
transcriptome analyses revealed different pathways of gene regulation in each type of reactive
astrocytes

41

. Identifying the type of activated astrocytes and their distribution in the PGJ2-

induced rat model of neuroinflammation could help establish the direction to target the reactive
astrocytes in PD: whether to increase or reduce astrocyte activation to attain the best possible
therapeutic benefit and potentially determine the most opportune time for therapeutic
intervention.
2. Investigate the distribution and levels of elements of the prostaglandin D2/J2 pathway in
non-DA neurons outside the SNpc, and correlate them with PD-like symptoms at the
molecular and behavior levels over longer periods of time – The PGJ2-induced rat model of
neuroinflammation exhibits progressive DA neuronal degeneration in the SNpc, as confirmed by
immunohistochemical analyses at four and eight weeks post the last PGJ2-injection.
Furthermore, µPET studies with the dopamine transporter (DAT) radioligand [11C]PE2i showed
that pre-synaptic neuronal degeneration progressively worsens in the PGJ2-treated rats until 26
weeks post-injection (unpublished data by our Weill Cornell Medicine collaborators: Dr.
Anastasia Nikolopoulou, Dr. Yeona Kang, and Dr. John Babich). Based on our studies, it is
possible that disease progression is caused by toxic effects associated with the increased
activation of microglia and sustained astrogliosis. We speculate that the observed persistent
76

gliosis is mediated by high levels of PGD2 and PGJ2 derived from L-PGDS, resulting in higher
DP2 activation. Some of the mechanisms that could be triggered by higher PGD2/J2 levels and
DP2 activation could include apoptosis, oxidative stress, mitochondrial dysfunction and
abnormal protein modification. These processes are involved in the initiation and progression of
PD associated with chronic neuroinflammation (reviewed in

24

). It is important to investigate if

these processes are induced in the PGJ2 rat model over a longer span of time, and if they mediate
the spread of the disease to other brain regions beside the SNpc, as well as to non-DA neurons,
and how they relate to non-motor PD-associated symptoms.
3. Assess the progression of neuroinflammation linked to activated microglia and reactive
astrocytes, and investigate their interactions in vivo by testing novel PET tracers – The
radioligand [11C]PK11195 has been widely used in CNS studies since the 1980s

TSPO

(reviewed in

232

). The [11C]PK11195 signal has been considered to be specific for activated

microglia during neuroinflammation associated with brain injuries as well as PD 233. More recent
studies report that TSPO is also overexpressed in reactive astrocytes

234

, which can thus be

detected by PET imaging with [11C]PK11195 212. Therefore, the [11C]PK11195 signal detected in
the PGJ2-treated rats represents the summation of both microglia and astrocyte activation.
Alternative radioligands are necessary to be able to discriminate between reactive
astrocytes and activated microglia to study their temporal interactions along the progression of
PD-like pathology. Radiotracer development for reactive astrocytes is still in a premature phase.
235

In contrast, various microglia targets are being explored and validated. For example, the

purinergic receptor 2 ion channel receptor (P2X7R), is potentially specific to the proinflammatory subtype of microglia, and is currently considered relevant to neurodegenerative
diseases

236

. P2X7R-targeting with [11C]GSK1482160 has been tested in LPS-treated mice and
77

may potentially serve as a neuroinflammatory biomarker 237.
Additionally, in the PGJ2-induced rat model, in vivo assessment of elements of the
prostaglandin D2/J2 pathway downstream of cyclooxygenases, could lead to the identification of
novel PD biomarkers. For example, we speculate that µPET imaging with [18F] FBuEA-GS, a
radio-labeled fluorobutyl ethacrynic glutathione conjugate amide, could be used as a potential
biomarker for PD diagnosis. This radioligand specifically binds to L-PGDS, and has been used
for imaging high-grade gliomas, which are brain tumors

200

. [18F] FBuEA-GS could be used to

detect L-PGDS changes in the SNpc DA neurons and microglia in PD patients. Using the PGJ2induced rat model, we could attempt to correlate L-PGDS level and glial activation or neuronal
loss in vivo. The PGJ2-induced rat model of neuroinflammation is thus optimal to test such novel
radioligands.
4. Explore novel therapeutic strategies for PD – In the PGJ2-induced rat model, we
characterized the distribution and levels of elements of the prostaglandin D2/J2 pathway, that
included COX-2, the PGD2 synthase L-PGDS, the DP2 receptor, and the prostaglandin
dehydrogenase 15-PGDH. Based on our data, we speculate that potential novel therapeutic
strategies for PD could include inhibiting L-PGDS activity, stimulating the DP1 receptor, and
blocking the DP2 receptor, to protect DA neurons in the SNpc against neurotoxicity associated
with neuroinflammation. Future studies could test the following drugs:
1)

AT-56

(4-(5H-dibenzo[a,d]cyclohepten-5-ylidene)-1-[4-(2H-tetrazol-5-yl)-butyl]-

piperidine), a selective L-PGDS inhibitor. Previous studies showed that serum starvation
increased PGD2 synthesis by ~2-fold in human-derived medulloblastoma cells (TE671), and that
AT-56 treatment was effective in reducing PGD2

238

. In another study, PGD2 levels were

increased from 0.23 ng to 118 ng / brain in H-PGDS-deficient mice in response to a stab wound
78

239

. PGD2 levels were significantly reduced up to 40%, by oral treatment one hour prior to the

injury, with AT-56 in a dose-dependent manner (3, 10, 30 mg / kg of AT-56)
human enteric nervous system (ENS) expresses L-PGDS, not H-PGDS

240

cultures treated with LPS, AT-56 significantly reduced PGD2 synthesis
dysfunction is a very common symptom in PD

241

239

. Inflamed

. In rat ENS primary

240

. As gastrointestinal

, AT-56 may be used to investigate the

relevance of L-PGDS to this non-motor type of PD pathology.
2) BW245C, a DP1-selective agonist. BW245C was shown to rescue rat hippocampal
neuronal cultures from NMDA-induced toxicity by eliciting a rapid increase in the production of
cAMP

101

. Intracerebroventricular pre-treatment with BW245C (10 – 50 nM) lowered the

NMDA-induced brain lesion size in young and old mice in a dose-dependent manner

216

.

However, the in vivo effect of BW245C must be considered with caution, as DP1 receptors are
expressed not only in neurons but also in microglia and astrocytes

218

. When mouse primary

cortical neurons pre-treated with BW245C, were combined with primary microglia cultures,
microglia activation was observed 220.
3) BAY-u3405 (ramatroban), a known antagonist of DP2 and thromboxane receptors.
BAY-u3405 has been marketed for allergic rhinitis in Japan 242, and its analogue CAY10471 is a
highly potent and selective DP2 antagonist
model of neuropathic pain

195

hippocampal neuronal culture

,

243

. CAY10471 was shown to reduce pain in a rat

and to diminish aluminum-induced toxicity in rat primary
196

. Recent studies suggest that emotional impairment and

depression-related behaviors are mediated by DP2-receptor activation

244

. In these studies,

intracerebroventricular injection of LPS caused anxiety and decreased social behavior in wildtype mice, but DP2-deficient mice were protected

244

. DP2-deficient mice were also resistant to

chronic stress induced-depression resulting from chronic corticosterone treatment
79

245

. The LPS-

induced emotional behaviors in wild-type mice were reversed by both DP2 antagonists,
administered systemically for ramatroban (30mg / kg) or via intracerebroventricular injections
for CAY10471 (1 nM) 244. The corticosterone-induced depressive behavior was also significantly
reduced by intraperitoneal (i.p.) injections of ramatroban (30mg / kg)

245

. Considering the

prevalence of anxiety and apathy (30% - 40%) and depression (15% – 50%) among PD patients
246

, DP2 antagonists could be therapeutically effective to treat non-motor PD symptoms, in

addition to preventing the SN DA neuronal loss associated with chronic neuroinflammation.
Taken together, these novel drugs could be tested alone or in combination with ibuprofen
to improve therapeutic effectiveness against neuroinflammation, in relation to motor and nonmotor symptoms of PD. The progressive nature of neurodegeneration exhibited by the PGJ2induced rats offers an advantage for comparing the therapeutic effectiveness of novel drugs. As it
develops progressive PD-like pathology, the PGJ2-induced rat model of neuroinflammation is an
optimal model to expand our knowledge of PD progression, to test novel tracers for PET imaging
in PD, and to develop new therapeutic targets and biomarkers for PD.
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Fig. 5.1. Scheme depicting novel therapeutic agents and PET radiotracers (in green) that, based on
our studies, could have potential to treat and diagnose PD. 1 - DP2 receptor antagonists: in the
SNpc, DP2 receptors were detected in dopaminergic neurons but not in microglia. DP2 receptor
activation leads to a decrease in cAMP and an increase in calcium. These effects mediate
neurotoxicity induced by DP2 receptor activation. Thus, DP2 receptor antagonists could potentially
prevent DA neurodegeneration. 2 – L-PGDS inhibitors: in the brain, this enzyme synthesizes PGD2
from PGH2. PGD2 and its metabolite PGJ2 can be neurotoxic. Thus, decreasing L-PGDS activity will
lower PGD2 levels and could prevent or diminish the neurotoxic effects of PGD2/J2 on dopaminergic
neurons. 3 – L-PGDS radiotracer: L-PGDS is highly abundant in DA neurons, microglia, and CSF.
18
The radiotracer [ F] FBuEA-GS has been used for PET analysis of high-grade gliomas. We propose
that this radioligand could be an optimal reagent to assess changes in neuroinflammation linked to
PD. COX 1 and 2, cyclooxygenase 1 and 2; L-PGDS, lipocalin prostaglandin D synthase; 15-PGDH,
15-hydroxyprostaglandin dehydrogenase; [18F]FBuEA-GS, glutathione conjugate of fluorine-18labeled fluorobutyl ethacrynic amide; PPARγ, peroxisome proliferator-activated receptor gamma; PET,
positron emission tomography. For more details see chapter 5.
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